var title_f16_57_17296="Osteoarthritis of the elbow";
var content_f16_57_17296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Osteoarthritis of the elbow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 472px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe joint space narrowing and sclerosis of the articular bone surfaces (arrow) is evident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17296=[""].join("\n");
var outline_f16_57_17296=null;
var title_f16_57_17297="Anatomy of hypothalamus";
var content_f16_57_17297=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the hypothalamic-pituitary region",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral view of the brain showing the relationship of the hypothalamus to the median eminence and the pituitary gland.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Krieger DT, in: Neuroendocrinology, Krieger DT, Hughes JC (Eds), Sinauer Associates, Sunderland, MA, 1980, p. 4.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17297=[""].join("\n");
var outline_f16_57_17297=null;
var title_f16_57_17298="Kawasakis disease - targetoid";
var content_f16_57_17298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Kawasaki&rsquo;s disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous plaques, some with a targetoid appearance, are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17298=[""].join("\n");
var outline_f16_57_17298=null;
var title_f16_57_17299="Acetylcholine: Patient drug information";
var content_f16_57_17299=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acetylcholine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"     see \"Acetylcholine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/5/27730?source=see_link\">",
"     see \"Acetylcholine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Miochol&reg;-E",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F130091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Miochol&reg;-E",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during eye surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701433",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acetylcholine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703773",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have swelling in parts of the eye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697908",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11472 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17299=[""].join("\n");
var outline_f16_57_17299=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130090\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130091\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015277\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015276\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015279\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015280\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015282\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015283\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015284\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=related_link\">",
"      Acetylcholine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/5/27730?source=related_link\">",
"      Acetylcholine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_57_17300="Zinc sulfate: Drug information";
var content_f16_57_17300=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zinc sulfate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/38/4708?source=see_link\">",
"    see \"Zinc sulfate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/39/29301?source=see_link\">",
"    see \"Zinc sulfate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Orazinc&reg; 110 [OTC];",
"     </li>",
"     <li>",
"      Orazinc&reg; 220 [OTC];",
"     </li>",
"     <li>",
"      Zinc 15 [OTC];",
"     </li>",
"     <li>",
"      Zincate&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anuzinc;",
"     </li>",
"     <li>",
"      Rivasol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F235819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Trace Element",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F235814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Oral (dose expressed as elemental zinc): Adults &ge;19 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males: 11 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: 8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnancy: 11 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lactation: 12 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parenteral TPN:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Acute metabolic states:",
"     </i>",
"     4.5-6 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Metabolically stable:",
"     </i>",
"     2.5-4 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Replacement for small bowel fluid loss (metabolically stable):",
"     </i>",
"     An additional 12.2 mg zinc/L of fluid lost, or an additional 17.1 mg zinc per kg of stool or ileostomy output",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F235816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/39/29301?source=see_link\">",
"      see \"Zinc sulfate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Oral (dose expressed as elemental zinc): 1&ndash;6 months: 2.0 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Oral (dose expressed as elemental zinc):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: 3 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 3 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 11 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 9 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Pregnancy: 12 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Lactation: 13 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parenteral TPN:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants (premature, birth weight &lt;1500 g up to 3 kg): 300 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants (full term) and Children &le;5 years: 100 mcg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F235815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 220 mg [elemental zinc 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orazinc&reg; 220: 220 mg [elemental zinc 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zincate&reg;: 220 mg [DSC] [elemental zinc 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: Elemental zinc 1 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate, preservative free]: Elemental zinc 5 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 220 mg [elemental zinc 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orazinc&reg; 110: 110 mg [elemental zinc 25 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zinc 15: 66 mg [elemental zinc 15 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F235805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zinc supplement (oral and parenteral); may improve wound healing in those who are deficient",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F554161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       ZnSO",
"       <sub>",
"        4",
"       </sub>",
"       is an error-prone abbreviation (mistaken as  morphine sulfate)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F235817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, diarrhea, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13881522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Injection: Do not administer undiluted into peripheral vein",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13881523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;\">",
"     &bull; Copper: I.V. administration of zinc without copper may cause a decrease in copper serum concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Aluminum: Solutions may contain aluminum; toxic concentrations may occur following prolonged administration in premature neonates or patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ceftibuten: Zinc Salts may decrease the serum concentration of Ceftibuten.  Management: Consider administering oral zinc salts at least 3 hours after ceftibuten.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalexin: Zinc Salts may decrease the absorption of Cephalexin.  Management: Consider administering oral zinc salts at least 3 hours after cephalexin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Zinc Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Zinc Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., zinc-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Zinc Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Zinc Salts may decrease the absorption of Tetracycline Derivatives. Only a concern when both products are administered orally.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Zinc Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Zinc Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F235811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Avoid foods high in calcium or phosphorus.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13881520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zinc crosses the placenta and can be measured in the cord blood and placenta. Fetal concentrations are regulated by the placenta (de Moraes, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13881521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zinc is found in breast milk; concentrations decrease over the first 6 months of lactation. Concentrations are generally not affected by dietary supplementation (IOM, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F235808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food if GI upset occurs.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F235807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Orazinc Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220 mg (100): $7.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Zinc Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220 mg (100): $4.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Eye-Sed Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.217% (15 mL): $3.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zinc Sulfate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (10 mL): $3.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (5 mL): $4.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Orazinc Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     110 mg (100): $4.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zinc 15 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     66 mg (100): $1.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zinc Gluconate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $3.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zinc Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220 mg (100): $7.50",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Afazol Z (MX);",
"     </li>",
"     <li>",
"      Avazinc (IL);",
"     </li>",
"     <li>",
"      Dalidome (MX);",
"     </li>",
"     <li>",
"      Daribur (MX);",
"     </li>",
"     <li>",
"      Exastrin (MX);",
"     </li>",
"     <li>",
"      Solvazinc (GB);",
"     </li>",
"     <li>",
"      Solvezink (NO, SE);",
"     </li>",
"     <li>",
"      Vytral (MX);",
"     </li>",
"     <li>",
"      Zincol (IL);",
"     </li>",
"     <li>",
"      Zincteral (CZ, PL)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      de Moraes ML, de Faria Barbosa R, Santo RE, et al, \"Maternal-Fetal Distribution of Calcium, Iron, Copper, and Zinc in Pregnant Teenagers and Adults,\"",
"      <i>",
"       Biol Trace Elem Res",
"      </i>",
"      , 2011, 139(2):126-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/57/17300/abstract-text/20195918/pubmed\" id=\"20195918\" target=\"_blank\">",
"        20195918",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: National Academy Press, 2000.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10328 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-FB51BAF4EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17300=[""].join("\n");
var outline_f16_57_17300=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235812\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235813\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235819\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235814\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235816\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235815\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235804\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235793\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235805\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F554161\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235817\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13881522\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13881523\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300239\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223740\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235811\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235800\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13881520\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13881521\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235808\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235807\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869420\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10328\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10328|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/38/4708?source=related_link\">",
"      Zinc sulfate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/39/29301?source=related_link\">",
"      Zinc sulfate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_57_17301="Diagram of human eye";
var content_f16_57_17301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Anatomy of the eye",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 590px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17301=[""].join("\n");
var outline_f16_57_17301=null;
var title_f16_57_17302="Depth invasion esophageal cancer";
var content_f16_57_17302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subclassification of the depth of superficial esophageal cancer (number of patients)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 215px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Proportion of patients without recurrence of Barrett's esophageal cancer according to depth of invasion after esophagectomy (from Westerterp M et al, Virchows Arch 2005; 446:497).",
"    <div class=\"footnotes\">",
"     Ep: epithelial layer; lpm: lamina propria; mm: muscularis mucosa; sm: submucosa; mp: muscularis propria.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shimada H, Nabeya Y, Matsubara H, et al. Prediction of lymph node status in patients with superficial esophageal carcinoma: analysis of 160 surgically resected cancers. Am J Surg 2006; 191:250. Copyright &copy;2006 Excerpta Medica Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17302=[""].join("\n");
var outline_f16_57_17302=null;
var title_f16_57_17303="Conventional pancreaticoduodenectomy";
var content_f16_57_17303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Conventional pancreaticoduodenectomy (Whipple procedure)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 663px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17303=[""].join("\n");
var outline_f16_57_17303=null;
var title_f16_57_17304="The impact of breastfeeding on the development of allergic disease";
var content_f16_57_17304=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The impact of breastfeeding on the development of allergic disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/57/17304/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/57/17304/contributors\">",
"     David M Fleischer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/57/17304/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/57/17304/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/57/17304/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/57/17304/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/57/17304/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human milk is the optimal source of nutrition for term infants during the first six months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/1\">",
"     1",
"    </a>",
"    ]. Breastfeeding for all infants is strongly supported by both governmental and medical professional organizations because of its acknowledged benefits with respect to nutrition, gastrointestinal function, immediate protection from infectious disease, and psychological well being [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In addition, epidemiologic studies suggest that breastfeeding contributes to protection against childhood inflammatory, autoimmune, and malignant diseases, suggesting an impact on longer-term immune function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association between breastfeeding and lower rates of eczema in infants was first reported more than 75 years ago [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/4\">",
"     4",
"    </a>",
"    ]. A body of evidence has subsequently developed that has examined the impact of breastfeeding on the development of allergic disease, although definitive conclusions are not yet possible [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the literature examining the effects of breastfeeding on the prevention of allergic diseases, including atopic dermatitis (AD), asthma, allergic rhinitis (AR), and food allergy. Other aspects of the primary prevention of allergic disease are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20119?source=see_link\">",
"     \"Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMMUNOLOGIC PROPERTIES OF BREAST MILK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human breast milk contains a variety of immunologically active substances, including immunoglobulins, antimicrobial enzymes, and various leukocytes. It also contains antiinflammatory and tolerance-promoting compounds, such as polyunsaturated long-chain fatty acids, platelet activating factor (PAF)-acetylhydrolase, and interleukin-10 (IL-10). Additionally, a variety of agonists and antagonists of the innate immune responses, including CD-14 and factors that modulate toll-like receptor (TLR) signaling, have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. However, a simple relationship between these components and the atopic state of the mother or infant has not been apparent in most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Theories about how these immunologically active components of breast milk may interact with the neonatal immune system include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study in mice demonstrated that airborne allergens inhaled by lactating females and ingested with breast milk by nursing offspring stimulated the induction of regulatory T cells and allergen-specific tolerance [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/14\">",
"       14",
"      </a>",
"      ]. The presence of transforming growth factor (TGF)-beta was critical for this interaction.",
"     </li>",
"     <li>",
"      Breast milk may buffer the neonatal intestine against infectious organisms while simultaneously providing probiotic organisms, resulting in subclinical infections that stimulate beneficial immunologic responses without excessive inflammation or tissue damage [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The immunologic development of the newborn gut may be influenced both by the early presence of breast milk and by dynamic changes in milk that occur during the course of lactation, leading to lasting effects on immune function [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Breast milk, compared with formula, has been shown in animal models to inhibit the increase in food antigen absorption that occurs postnatally, although the responsible mechanism is not known [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/17\">",
"       17",
"      </a>",
"      ]. Prospective studies in humans have not shown a protective effect of breast milk-specific antibodies on infant sensitization (eg, anti-egg antibodies in breast milk do not prevent infant sensitization to egg) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGIC ISSUES IN BREASTFEEDING STUDIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infants at high risk for developing allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In studies of primary allergy prevention, an infant is defined as \"high-risk\" for developing allergic disease if there is at least one first degree relative (parent or sibling) with a documented allergic condition. This definition is based upon a consensus among several committees representing the American Academy of Pediatrics (AAP), the joint guidelines of the European Society for Pediatric Allergology and Clinical Immunology (ESPACI), and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This definition of high-risk is broad, however. An infant may be at high-risk because the father has allergic rhinitis or because multiple siblings have severe asthma and life-threatening food allergy. These two infants are clearly not at equivalent risk. The general nature of this definition ensures that the findings of studies can be applied to significant portions of the general population, although it also may combine higher and lower risk infants, in whom the impact of breastfeeding may differ.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sources of bias and confounding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiologic rigor of studies involving breastfeeding is compromised by the inability to ethically randomize subjects to breastfeeding or formula feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/20\">",
"     20",
"    </a>",
"    ]. Most of the literature is therefore limited to observational studies, and it is difficult to determine causality in such studies.",
"   </p>",
"   <p>",
"    There are several other potential sources of bias in breastfeeding studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who breastfeed often practice other health-promoting activities, such as not smoking.",
"     </li>",
"     <li>",
"      Breastfed children may be enrolled less often in day care, or come from different socioeconomic strata, compared to formula-fed children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even when these differences have been accounted for as well as possible, the conclusions about the impact of breastfeeding must be viewed as potentially affected by \"residual\" confounding.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mothers who believe their infants are at higher risk for allergy (often correctly so) may be more likely to breastfeed, or to breastfeed longer. Therefore, the anticipated atopic state of the infant may influence the mother's behaviors, beginning as early as conception. This is referred to as reverse causation.",
"     </li>",
"     <li>",
"      Mothers whose infants begin to show signs of the disease in question may continue breastfeeding for longer, or more exclusively, than they may have otherwise &nbsp;a phenomenon called disease-related modification of exposure. To avoid this problem, investigators sometimes exclude those infants who developed the condition in question while still breastfeeding, such that the analysis is limited to those subjects in whom breastfeeding and the outcome in question are separated in time. However, this practice may introduce problems of its own.",
"     </li>",
"     <li>",
"      Variations in the duration and pattern of breastfeeding (never versus ever or exclusive versus partial) make comparisons between studies difficult.",
"     </li>",
"     <li>",
"      Breastfeeding does not usually stop the day formula or milk is introduced; weaning is often a gradual process that may take weeks to months, making it difficult to assess exposure dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these limitations however, it is possible to detect trends in the literature, as discussed below.",
"   </p>",
"   <p>",
"    A 2007 study introduced the novel approach of randomizing women and infants to an intervention to promote breastfeeding, which avoids the ethical issues of interfering directly with maternal choices about infant feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/21\">",
"     21",
"    </a>",
"    ]. Subjects were then followed prospectively for nearly seven years and skin tested after age six years for five common aeroallergens, although atopic disease was not the primary outcome of the study. The intervention resulted in a significant increase in exclusive breastfeeding at three months (43 compared to 6 percent), as well as higher rates of any breastfeeding through one year. However, the overall prevalence of asthma, AR, AD, and one or more positive skin tests was not statistically different between the two groups of children, indicating that exclusive and prolonged breastfeeding did not impact atopic disease. Potential problems with this study included the low overall prevalence of allergic disease in this population, and the fact that these findings represented secondary outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/22\">",
"     22",
"    </a>",
"    ]. Still, this approach may prove useful in future investigations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BREASTFEEDING AND ATOPIC DERMATITIS (ECZEMA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many observational studies have examined associations between breastfeeding and atopic dermatitis (AD). Some have suggested a protective effect [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/23-26\">",
"     23-26",
"    </a>",
"    ], whereas others have shown either no association [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/27,28\">",
"     27,28",
"    </a>",
"    ] or even a detrimental effect [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Modification by family history of atopy is also variable [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Overall, the literature suggests that exclusive breastfeeding for at least three to four months is not associated with a lower incidence of eczema in either low-risk or high-risk infants.",
"   </p>",
"   <p>",
"    A 2009 systematic review and meta-analysis of prospective cohort studies in developed countries compared breastfeeding with conventional infant formula feeding or partial breastfeeding on the development of AD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/34\">",
"     34",
"    </a>",
"    ]. Included were 21 studies of 34,227 subjects with a mean follow-up of 2.2 years (range one to seven years) that met standardized criteria. Analysis revealed that exclusive breastfeeding for at least three months was not significantly protective against the development of AD compared with partial breastfeeding or conventional formula (OR = 0.89; 95% CI 0.76-1.04). Exclusive breastfeeding, when compared to use of conventional formula, was associated with a decreased risk of AD (OR 0.7; 95% CI 0.5-0.99), but this effect was lost when a controversial study was excluded from the analysis. A significant effect was not seen when only cohorts with a positive family history of atopy were examined. There was substantial heterogeneity across studies.",
"   </p>",
"   <p>",
"    In sub-analyses, parent-reported AD was not reduced by breastfeeding, but physician-diagnosed AD was (OR 0.78; 95% CI 0.61-0.99) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, the more recent studies included in the meta-analysis showed less protective effects, accounting in part for different results of this meta-analysis compared with one published in 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/32\">",
"     32",
"    </a>",
"    ] that concluded that breastfeeding was protective of AD, particularly in atopic families. This decrease in protective effect may be due to better adjustment for confounders in the more recent studies or reverse causation (maternal proclivity toward continuing breastfeeding if their infant begins to develop eczema because of public awareness).",
"   </p>",
"   <p>",
"    The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two examined the association between breastfeeding and eczema in 51,119 children aged 8 to 12 years from both high and low income countries, representing the largest single study analysis of the association of breastfeeding and AD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/35\">",
"     35",
"    </a>",
"    ]. Information about breastfeeding and eczema was gathered from a parental questionnaire, and the children were examined for flexural eczema and skin tested to six common aeroallergens. There was a slight significant increased risk of ever having eczema in children ever breastfed; when the duration of breastfeeding was taken into account, a small increased risk was found for children who had been breastfed &lt;6 months, but no association was noted in children breastfed for &ge;6 months. Allergen sensitization and parental atopy did not modify these results. Limitations of the study include the potential for recall bias and reverse causation.",
"   </p>",
"   <p>",
"    Among the reports suggesting a protective effect, there was one prospective interventional study in which mothers were randomly assigned to receive assistance with initiating and maintaining breastfeeding, or routine postnatal follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/24\">",
"     24",
"    </a>",
"    ]. In this trial, 17,046 healthy mothers of full-term infants in Belarus were followed for 12 months. Multiple endpoints were examined, including incidence of gastrointestinal infections, eczema, and respiratory tract infections. The mothers who received assistance with initiating and maintaining breastfeeding were more likely to be exclusively breastfeeding at three and six months, and breastfeeding to some degree at 12 months. The occurrence of eczema was reduced by 46 percent in infants whose mothers received breastfeeding support, compared to infants whose mothers did not, although the findings just reached statistical significance (odds ratio [OR] = 0.54; 95% confidence interval [CI], 0.31-0.95).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BREASTFEEDING AND ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the association between breastfeeding and the development of asthma have also reached conflicting conclusions. Exclusive breastfeeding for three to four months is associated with reduced risk of recurrent wheezing through approximately age six years in most studies. However, there is preliminary evidence that the combination of an atopic infant and an asthmatic mother may result in a different outcome. More long-term studies are needed to confirm these findings before it is recommended to avoid breastfeeding in order to prevent later-onset asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Early versus late wheezing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"wheezing\" is used in this review to denote respiratory symptoms suggestive of asthma, including cough, difficulty breathing, wheezing, and breathlessness. Studies of asthma may be influenced by the period (infancy, early childhood, or adolescence) when recurrent wheezing or \"asthma\" outcomes are assessed, because asthmatic symptoms may be caused by different pathologic processes in these age groups.",
"   </p>",
"   <p>",
"    In the first year or two of life, wheezing is often associated with upper respiratory infections (URIs). The tendency of an infant to wheeze with URIs often resolves with age, and is not necessarily associated with the later development of asthma. In contrast, by school-age and adolescence, wheezing is more likely to represent atopic asthma and tends to be persistent. Some of the studies reviewed below attempted to distinguish between early recurrent virus-induced wheezing and later-onset, atopic wheezing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies with an apparent protective impact of breastfeeding typically examined asthma symptoms in the first few years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/31,38,39\">",
"     31,38,39",
"    </a>",
"    ]. Three large, prospective observational studies, in which children were assessed as infants through the age of six years, suggested a lower risk of asthma in infants who were exclusively breastfed for the first three to four months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/36,40,41\">",
"     36,40,41",
"    </a>",
"    ]. Breastfeeding has been shown to reduce the number of clinically significant respiratory tract infections in infants and would thus be expected to reduce wheezing associated with these infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/38,42-44\">",
"     38,42-44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, studies that followed children until adolescence found that breastfeeding was ultimately not protective against asthma in the highest risk infants [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/37,45\">",
"     37,45",
"    </a>",
"    ]. The Tucson Children's Respiratory Study included a prospective, longitudinal assessment of the risk factors for the development of asthma in childhood, in which 1246 healthy newborns at both high and average risk for atopic disease were followed for the first 13 years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/37\">",
"     37",
"    </a>",
"    ]. The relationship between breastfeeding and asthma or recurrent wheeze varied with the age of the child, the presence or absence of maternal asthma, and the child's atopic status, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all children in the first two years of life, exclusive breastfeeding for four or more months was associated with a lower risk of recurrent wheeze, regardless of the presence or absence of maternal asthma and atopy in the child.",
"     </li>",
"     <li>",
"      After age three, exclusive breastfeeding showed no association with recurrent wheezing for the cohort as a whole.",
"     </li>",
"     <li>",
"      Subgroup analysis concluded that for atopic children with asthmatic mothers, exclusive breastfeeding was associated with increased risk of recurrent wheeze after the age of six years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The latter findings imply some interaction between atopic children and asthmatic mothers that actually increases the risk of asthma in later childhood and adolescence. However, subgroup analysis within an observational study is a relatively weak form of evidence, and a subsequent study with similar design did not confirm these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A critical review of the literature and a meta-analysis have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Both of these included studies of children with and without family histories of atopy, to provide more generalizable conclusions about the impact of breastfeeding on asthma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of the literature pertaining to infant feeding and its relation to allergy development from 1966 to 2001 analyzed 56 studies [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/46\">",
"       46",
"      </a>",
"      ]. Any breastfeeding decreased the risk of recurrent wheezing in young children, which was possibly due to fewer respiratory infections, as discussed previously. Exclusive breastfeeding was associated with a reduced risk of asthma overall. Protection increased with the duration of breastfeeding as long as four months and seemed to persist at least during the first decade of life in all children regardless of atopic risk, although the beneficial effects were particularly strong in infants with atopic families.",
"     </li>",
"     <li>",
"      A systematic meta-analysis of prospective studies in developed countries published through 1999 evaluated the association between exclusive breastfeeding during the first three months after birth and asthma, and reached similar conclusions [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/47\">",
"       47",
"      </a>",
"      ]. Twelve studies with a total of 8183 subjects and mean follow-up time of 4.1 years were analyzed. Exclusive breastfeeding for at least three months after birth was protective for the development of asthma by two to five years of age. The protective effect estimate of breastfeeding was mainly seen in studies of children with a family history of atopy and was negligible in children who specifically did not have family histories of atopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies published since the systematic review and meta-analysis have shown somewhat conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The International Study of Asthma and Allergy in Childhood (ISAAC) Phase II evaluated the association between wheezing in the past year and history of breastfeeding in 54,943 children aged 8 to 12 years [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/48\">",
"       48",
"      </a>",
"      ]. Skin prick testing to aeroallergens was performed on 31,759 of these children. A history of any breastfeeding had a protective effect against any wheezing in the past year only in nonatopic children from nonaffluent countries. This study suggests that at least part of the variability in findings on the impact of breastfeeding on wheezing and asthma may be due to differences in the predominant wheezing phenotype (atopic versus nonatopic) in the study population.",
"     </li>",
"     <li>",
"      The Tasmanian Asthma Study followed a population-based cohort of over 8500 children born in 1961 prospectively from age 7 years until age 44 years to assess the relationship between exclusive breastfeeding for the first three months of life and asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/49\">",
"       49",
"      </a>",
"      ]. Subjects were initially surveyed at age seven years, and four follow-up surveys were performed at the ages of 13, 20, 31, and 44 years. At age seven years, exclusive breastfeeding of children with a maternal history of atopy resulted in marginal protection against asthma. The protective effect of breastfeeding was mainly in children who developed asthma before the age of three years, as more than 70 percent of these children no longer had current asthma by age 14 years. However, the risk was reversed by the age of 14 years, with breastfeeding becoming a risk factor for current asthma at ages 14, 32, and 44 years. The risk was highest in subjects who developed asthma after age seven years, rather than subjects with persistent asthma from childhood. Limitations of this study included recall bias since information on breastfeeding was gathered when the child was seven years old, reverse causation, and possible ascertainment bias due to the rising prevalence of asthma in the past 30 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BREASTFEEDING AND ALLERGIC RHINITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of breastfeeding on the development of AR remains controversial. A systemic meta-analysis of prospective studies from 1966 to 2000 evaluated the association between exclusive breastfeeding for at least three months and AR during a follow-up period of 2.25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/50\">",
"     50",
"    </a>",
"    ]. However, the high frequency of rhinitis due to URIs in young children, and the usual onset of AR after age three years made it difficult to distinguish between causes of rhinitis in this analysis. Based upon only six studies, an association was found between breastfeeding and reduced risk of AR, although it was not statistically significant (OR = 0.74; 95% CI 0.54-1.01).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     BREASTFEEDING AND FOOD ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a limited number of studies that have examined the impact of breastfeeding on the development of food allergies, and the results may be affected by other dietary variables, such as the length and extent of exclusive breastfeeding, as well as the concomitant presence of AD and asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/18,51,52\">",
"     18,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review found that there was evidence of an association between exclusive breastfeeding for at least four months and a lower cumulative incidence of cow's milk allergy until 18 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/53\">",
"     53",
"    </a>",
"    ]. However, there were no large, well-designed studies examining longer-term or more general associations.",
"   </p>",
"   <p>",
"    A subsequent observational study found higher rates of sensitization (specific IgE &gt;0.7",
"    <span class=\"nowrap\">",
"     kU/L)",
"    </span>",
"    and allergy (specific IgE &gt;2",
"    <span class=\"nowrap\">",
"     kU/L)",
"    </span>",
"    to egg in infants with AD who were breastfed compared with those who were formula fed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/52\">",
"     52",
"    </a>",
"    ]. There was no difference in family history of allergic disease between the breastfed and formula fed infants. The route of food allergen exposure cannot be confirmed, but this finding suggests exposure through breast milk. However, there were not statistically significant differences in sensitization or allergy to cow's milk or soy. These findings need to be confirmed with further studies.",
"   </p>",
"   <p>",
"    It is clear that intact allergens passed to the infant through breast milk can trigger allergic symptoms once food allergy has developed. Definitive studies with double-blind, placebo-controlled, food challenges have demonstrated that food-allergic infants develop symptoms from food proteins in breast milk, and avoidance of these foods in the lactating mother's diet leads to improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In conclusion, exclusive breastfeeding in the first four months of life may decrease the risk of cow's milk allergy in early childhood. A more general or long-term impact of breastfeeding on food allergies remains to be determined.",
"   </p>",
"   <p>",
"    The effect of breastfeeding on atopy outcomes may also be influenced by specific genetic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17304/abstract/54\">",
"     54",
"    </a>",
"    ]. Sensitization to food allergens were noted to be modified in breastfed infants with specific polymorphisms in the interleukin receptor &beta;1 (IL12RB1), Toll-like receptor 9 (TLR9), and thymic stromal lymphopoietin genes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38194?source=see_link\">",
"       \"Patient information: Deciding to breastfeed (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"       \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast milk is an immunologically active substance, and beneficial effects on the immediate and long-term immune function of the infant have been proposed, including the possible prevention of allergic diseases. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2\">",
"     'Immunologic properties of breast milk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluating the impact of breastfeeding poses epidemiologic challenges because infants are not randomly assigned to breastfeeding or formula feeding, and families who choose to breastfeed may be different from those who don't in ways that are not easily controlled for in studies. These factors make breastfeeding studies particularly prone to confounding and bias. Most of the available studies are observational reports identifying associations between breastfeeding and risk of allergic conditions. Typically, these studies focus on infants at high risk for developing allergic disease, as defined by having a parent or sibling with an allergic condition. There is a trend toward less of a protective effect of breastfeeding on atopy outcomes, possibly due to changing environmental factors, alterations in study designs, reverse causation, or other factors.(See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiologic issues in breastfeeding studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The literature suggests that exclusive breastfeeding for at least three to four months is",
"      <strong>",
"       not",
"      </strong>",
"      strongly associated with a lower incidence of eczema in either low-risk or high-risk infants. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Breastfeeding and atopic dermatitis (eczema)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breastfeeding appears to be associated with a lowered incidence of recurrent wheezing during the first two years of life, possibly by reducing the number of symptomatic respiratory infections in this period, as infections are a prominent cause of wheezing in infants and young children. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Breastfeeding and asthma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Early versus late wheezing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wheezing in later childhood is more likely to represent atopic asthma, and the associations between breastfeeding and this type of wheezing are unclear. Still, the benefits of breastfeeding on the general health of the child outweigh the potential drawbacks, regardless of the atopic status of the mother or child. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Meta-analyses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are insufficient studies upon which to draw conclusions about the impact of breastfeeding on the development of allergic rhinitis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Breastfeeding and allergic rhinitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exclusive breastfeeding in the first four months of life may decrease the risk of cow's milk allergy in early childhood. A more general or long-term impact of breastfeeding on food allergies remains to be determined. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Breastfeeding and food allergy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/1\">",
"      Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2012; 129:e827.",
"     </a>",
"    </li>",
"    <li>",
"     Department of Health and Human Services, Office on Women's Health. Breastfeeding: HHS Blueprint for Action on Breastfeeding. US Department of Health and Human Services, Washington, DC 2000.",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Breastfeeding: maternal and infant aspects. ACOG Educational Bulletin 258, American College of Obstetricians and Gynecologists, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/4\">",
"      Grulee CG, Sanford HN. The influence of breast and artificial feeding on infantile eczema. J Pediatr 1930; 9:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/5\">",
"      Pali-Sch&ouml;ll I, Renz H, Jensen-Jarolim E. Update on allergies in pregnancy, lactation, and early childhood. J Allergy Clin Immunol 2009; 123:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/6\">",
"      Duch&eacute;n K, Casas R, Fager&aring;s-B&ouml;ttcher M, et al. Human milk polyunsaturated long-chain fatty acids and secretory immunoglobulin A antibodies and early childhood allergy. Pediatr Allergy Immunol 2000; 11:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/7\">",
"      Firth MA, Shewen PE, Hodgins DC. Passive and active components of neonatal innate immune defenses. Anim Health Res Rev 2005; 6:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/8\">",
"      Labbok MH, Clark D, Goldman AS. Breastfeeding: maintaining an irreplaceable immunological resource. Nat Rev Immunol 2004; 4:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/9\">",
"      Armogida SA, Yannaras NM, Melton AL, Srivastava MD. Identification and quantification of innate immune system mediators in human breast milk. Allergy Asthma Proc 2004; 25:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/10\">",
"      LeBouder E, Rey-Nores JE, Rushmere NK, et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003; 171:6680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/11\">",
"      LeBouder E, Rey-Nores JE, Raby AC, et al. Modulation of neonatal microbial recognition: TLR-mediated innate immune responses are specifically and differentially modulated by human milk. J Immunol 2006; 176:3742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/12\">",
"      Rigotti E, Piacentini GL, Ress M, et al. Transforming growth factor-beta and interleukin-10 in breast milk and development of atopic diseases in infants. Clin Exp Allergy 2006; 36:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/13\">",
"      Snijders BE, Damoiseaux JG, Penders J, et al. Cytokines and soluble CD14 in breast milk in relation with atopic manifestations in mother and infant (KOALA Study). Clin Exp Allergy 2006; 36:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/14\">",
"      Verhasselt V, Milcent V, Cazareth J, et al. Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma. Nat Med 2008; 14:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/15\">",
"      Newburg DS, Walker WA. Protection of the neonate by the innate immune system of developing gut and of human milk. Pediatr Res 2007; 61:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/16\">",
"      Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007; 7:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/17\">",
"      Udall JN, Colony P, Fritze L, et al. Development of gastrointestinal mucosal barrier. II. The effect of natural versus artificial feeding on intestinal permeability to macromolecules. Pediatr Res 1981; 15:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/18\">",
"      Greer FR, Sicherer SH, Burks AW, et al. Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics 2008; 121:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/19\">",
"      H&oslash;st A, Koletzko B, Dreborg S, et al. Dietary products used in infants for treatment and prevention of food allergy. Joint Statement of the European Society for Paediatric Allergology and Clinical Immunology (ESPACI) Committee on Hypoallergenic Formulas and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Committee on Nutrition. Arch Dis Child 1999; 81:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/20\">",
"      Zeiger RS. Food allergen avoidance in the prevention of food allergy in infants and children. Pediatrics 2003; 111:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/21\">",
"      Kramer MS, Matush L, Vanilovich I, et al. Effect of prolonged and exclusive breast feeding on risk of allergy and asthma: cluster randomised trial. BMJ 2007; 335:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/22\">",
"      Silvers KM, Epton MJ, Frampton CM. Allergy after breast feeding: Study was not designed to test the hypothesis. BMJ 2007; 335:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/23\">",
"      Kull I, B&ouml;hme M, Wahlgren CF, et al. Breast-feeding reduces the risk for childhood eczema. J Allergy Clin Immunol 2005; 116:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/24\">",
"      Kramer MS, Chalmers B, Hodnett ED, et al. Promotion of Breastfeeding Intervention Trial (PROBIT): a randomized trial in the Republic of Belarus. JAMA 2001; 285:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/25\">",
"      Schoetzau A, Filipiak-Pittroff B, Franke K, et al. Effect of exclusive breast-feeding and early solid food avoidance on the incidence of atopic dermatitis in high-risk infants at 1 year of age. Pediatr Allergy Immunol 2002; 13:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/26\">",
"      Laubereau B, Brockow I, Zirngibl A, et al. Effect of breast-feeding on the development of atopic dermatitis during the first 3 years of life--results from the GINI-birth cohort study. J Pediatr 2004; 144:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/27\">",
"      Ludvigsson JF, Mostrom M, Ludvigsson J, Duchen K. Exclusive breastfeeding and risk of atopic dermatitis in some 8300 infants. Pediatr Allergy Immunol 2005; 16:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/28\">",
"      Snijders BE, Thijs C, Kummeling I, et al. Breastfeeding and infant eczema in the first year of life in the KOALA birth cohort study: a risk period-specific analysis. Pediatrics 2007; 119:e137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/29\">",
"      Bergmann RL, Diepgen TL, Kuss O, et al. Breastfeeding duration is a risk factor for atopic eczema. Clin Exp Allergy 2002; 32:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/30\">",
"      Pesonen M, Kallio MJ, Ranki A, Siimes MA. Prolonged exclusive breastfeeding is associated with increased atopic dermatitis: a prospective follow-up study of unselected healthy newborns from birth to age 20 years. Clin Exp Allergy 2006; 36:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/31\">",
"      Giwercman C, Halkjaer LB, Jensen SM, et al. Increased risk of eczema but reduced risk of early wheezy disorder from exclusive breast-feeding in high-risk infants. J Allergy Clin Immunol 2010; 125:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/32\">",
"      Gdalevich M, Mimouni D, David M, Mimouni M. Breast-feeding and the onset of atopic dermatitis in childhood: a systematic review and meta-analysis of prospective studies. J Am Acad Dermatol 2001; 45:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/33\">",
"      Snijders BE, Thijs C, Dagnelie PC, et al. Breast-feeding duration and infant atopic manifestations, by maternal allergic status, in the first 2 years of life (KOALA study). J Pediatr 2007; 151:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/34\">",
"      Yang YW, Tsai CL, Lu CY. Exclusive breastfeeding and incident atopic dermatitis in childhood: a systematic review and meta-analysis of prospective cohort studies. Br J Dermatol 2009; 161:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/35\">",
"      Flohr C, Nagel G, Weinmayr G, et al. Lack of evidence for a protective effect of prolonged breastfeeding on childhood eczema: lessons from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. Br J Dermatol 2011; 165:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/36\">",
"      Kull I, Almqvist C, Lilja G, et al. Breast-feeding reduces the risk of asthma during the first 4 years of life. J Allergy Clin Immunol 2004; 114:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/37\">",
"      Wright AL, Holberg CJ, Taussig LM, Martinez FD. Factors influencing the relation of infant feeding to asthma and recurrent wheeze in childhood. Thorax 2001; 56:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/38\">",
"      Elliott L, Henderson J, Northstone K, et al. Prospective study of breast-feeding in relation to wheeze, atopy, and bronchial hyperresponsiveness in the Avon Longitudinal Study of Parents and Children (ALSPAC). J Allergy Clin Immunol 2008; 122:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/39\">",
"      Hide DW, Guyer BM. Clinical manifestations of allergy related to breast and cows' milk feeding. Arch Dis Child 1981; 56:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/40\">",
"      Oddy WH, Holt PG, Sly PD, et al. Association between breast feeding and asthma in 6 year old children: findings of a prospective birth cohort study. BMJ 1999; 319:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/41\">",
"      Silvers KM, Frampton CM, Wickens K, et al. Breastfeeding protects against current asthma up to 6 years of age. J Pediatr 2012; 160:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/42\">",
"      Wright AL, Holberg CJ, Martinez FD, et al. Breast feeding and lower respiratory tract illness in the first year of life. Group Health Medical Associates. BMJ 1989; 299:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/43\">",
"      Holberg CJ, Wright AL, Martinez FD, et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol 1991; 133:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/44\">",
"      Howie PW, Forsyth JS, Ogston SA, et al. Protective effect of breast feeding against infection. BMJ 1990; 300:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/45\">",
"      Sears MR, Greene JM, Willan AR, et al. Long-term relation between breastfeeding and development of atopy and asthma in children and young adults: a longitudinal study. Lancet 2002; 360:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/46\">",
"      van Odijk J, Kull I, Borres MP, et al. Breastfeeding and allergic disease: a multidisciplinary review of the literature (1966-2001) on the mode of early feeding in infancy and its impact on later atopic manifestations. Allergy 2003; 58:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/47\">",
"      Gdalevich M, Mimouni D, Mimouni M. Breast-feeding and the risk of bronchial asthma in childhood: a systematic review with meta-analysis of prospective studies. J Pediatr 2001; 139:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/48\">",
"      Nagel G, B&uuml;chele G, Weinmayr G, et al. Effect of breastfeeding on asthma, lung function and bronchial hyperreactivity in ISAAC Phase II. Eur Respir J 2009; 33:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/49\">",
"      Matheson MC, Erbas B, Balasuriya A, et al. Breast-feeding and atopic disease: a cohort study from childhood to middle age. J Allergy Clin Immunol 2007; 120:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/50\">",
"      Mimouni Bloch A, Mimouni D, Mimouni M, Gdalevich M. Does breastfeeding protect against allergic rhinitis during childhood? A meta-analysis of prospective studies. Acta Paediatr 2002; 91:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/51\">",
"      H&oslash;st A, Halken S, Muraro A, et al. Dietary prevention of allergic diseases in infants and small children. Pediatr Allergy Immunol 2008; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/52\">",
"      Han Y, Chung SJ, Kim J, et al. High sensitization rate to food allergens in breastfed infants with atopic dermatitis. Ann Allergy Asthma Immunol 2009; 103:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/53\">",
"      Muraro A, Dreborg S, Halken S, et al. Dietary prevention of allergic diseases in infants and small children. Part III: Critical review of published peer-reviewed observational and interventional studies and final recommendations. Pediatr Allergy Immunol 2004; 15:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17304/abstract/54\">",
"      Hong X, Wang G, Liu X, et al. Gene polymorphisms, breast-feeding, and development of food sensitization in early childhood. J Allergy Clin Immunol 2011; 128:374.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5746 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-DA858D2583-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17304=[""].join("\n");
var outline_f16_57_17304=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMMUNOLOGIC PROPERTIES OF BREAST MILK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGIC ISSUES IN BREASTFEEDING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infants at high risk for developing allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sources of bias and confounding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BREASTFEEDING AND ATOPIC DERMATITIS (ECZEMA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BREASTFEEDING AND ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Early versus late wheezing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BREASTFEEDING AND ALLERGIC RHINITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      BREASTFEEDING AND FOOD ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=related_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38194?source=related_link\">",
"      Patient information: Deciding to breastfeed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20119?source=related_link\">",
"      Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_57_17305="Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack";
var content_f16_57_17305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/57/17305/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/57/17305/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/57/17305/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/57/17305/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/57/17305/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/57/17305/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/57/17305/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/57/17305/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/57/17305/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a major risk factor for stroke and transient ischemic attack, with the risk increasing with every rise in systolic blood pressure (BP) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/1\">",
"     1",
"    </a>",
"    ]. The cardiovascular risk can be minimized by persistent correction of the hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\", section on 'Hypertension control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link&amp;anchor=H5#H5\">",
"     \"Hypertension: Who should be treated?\", section on 'Decreased cardiovascular risk with therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the stroke has stabilized, antihypertensive therapy can reduce the rate of recurrent stroke,",
"    <strong>",
"     independent of the baseline blood pressure",
"    </strong>",
"    . (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Trials of long-term antihypertensive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic will review the long-term role of antihypertensive therapy for prevention of a recurrent stroke. The major randomized trials will be reviewed followed by discussions of specific issues, such as when to lower the blood pressure, the choice of antihypertensive drugs, the blood pressure goal in relation to the presence or absence of large artery stenosis, and the rate of blood pressure reduction.",
"   </p>",
"   <p>",
"    The approach is determined by the degree of hypertension and by the type of stroke that is present: thromboembolic stroke; or intracerebral or subarachnoid hemorrhage. The diagnosis of stroke subtypes and risk factor reduction for the secondary prevention of stroke other than blood pressure control are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Acute stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hypertension may be an immediate concern in patients with an acute ischemic stroke and those with a subarachnoid or intracerebral hemorrhage. Blood pressure management in the acute phase of stroke is different from chronic therapy and is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link&amp;anchor=H14#H14\">",
"     \"Initial assessment and management of acute stroke\", section on 'Blood pressure management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H18#H18\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Blood pressure control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Intracranial pressure and blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRIALS OF LONG-TERM ANTIHYPERTENSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of long-term antihypertensive therapy to prevent recurrent stroke as well as other cardiovascular complications has been evaluated in a number of randomized, placebo-controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/3\">",
"     3",
"    </a>",
"    ]. All of the major trials included an angiotensin converting enzyme inhibitor or angiotensin receptor blocker. This section will review the findings in the two largest placebo-controlled trials and in meta-analyses. Trials comparing the efficacy of different antihypertensive drugs are discussed below. (See",
"    <a class=\"local\" href=\"#H12986312\">",
"     'Which antihypertensive drugs should be used?'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     PROGRESS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PROGRESS trial included over 6100 patients (mean age 64 years) with an ischemic or, less often, hemorrhagic stroke or transient ischemic attack within the previous five years (median eight months) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/4\">",
"     4",
"    </a>",
"    ]. The patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    or placebo; the diuretic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35846?source=see_link\">",
"     indapamide",
"    </a>",
"    was added as necessary in the perindopril group. The mean baseline blood pressure was",
"    <span class=\"nowrap\">",
"     147/86",
"    </span>",
"    mmHg; approximately one-half of patients were hypertensive (mean",
"    <span class=\"nowrap\">",
"     159/94",
"    </span>",
"    mmHg), while remaining patients had high-normal values (mean",
"    <span class=\"nowrap\">",
"     136/79",
"    </span>",
"    mmHg).",
"   </p>",
"   <p>",
"    The following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in blood pressure of",
"      <span class=\"nowrap\">",
"       9/4",
"      </span>",
"      mmHg in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"       perindopril",
"      </a>",
"      group compared with placebo decreased the rate of the primary end point of fatal or nonfatal stroke (10 versus 14 percent with placebo, relative risk reduction 28 percent, 95% CI 17 to 38 percent). Active therapy also reduced the risk of all cardiovascular events by 26 percent, and, although the number of events was small, significantly reduced the rate of intracerebral hemorrhage by 50 percent (1.2 versus 2.4 percent).",
"     </li>",
"     <li>",
"      The stroke prevention benefit was related to the degree of blood pressure reduction, being most prominent (relative risk reduction 43 percent) and statistically significant in patients treated with combination therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"       perindopril",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35846?source=see_link\">",
"       indapamide",
"      </a>",
"      ) who had a",
"      <span class=\"nowrap\">",
"       12/5",
"      </span>",
"      mmHg mean reduction in blood pressure compared with placebo. In comparison, patients treated with perindopril alone had only a",
"      <span class=\"nowrap\">",
"       5/3",
"      </span>",
"      mmHg mean reduction in blood pressure and a small and not significant benefit (relative risk reduction 5 percent). The reductions in blood pressure were similar in the hypertensive and high-normal blood pressure groups.",
"     </li>",
"     <li>",
"      The reduction in recurrent stroke with antihypertensive therapy was seen in both hypertensive (11.1 versus 16.2 percent, relative risk reduction 32 percent) and nonhypertensive patients (9.1 versus 11.5 percent, relative risk reduction 21 percent). Thus, both the risk of stroke and the absolute benefit from antihypertensive therapy were greater in the hypertensive patients. Similar findings were noted when all major vascular events were evaluated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A post hoc analysis from PROGRESS addressed the issue of whether the baseline blood pressure affected the response to antihypertensive therapy, including the possibility that patients with normal blood pressure (&lt;120 mmHg systolic) at baseline might be harmed from such therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/6\">",
"     6",
"    </a>",
"    ]. Among patients in the combination therapy arm, the relative risk reduction in stroke was",
"    <strong>",
"     similar",
"    </strong>",
"    <strong>",
"     at all levels",
"    </strong>",
"    of baseline systolic pressure (ranging from &lt;120 to &ge;160 mmHg). Although this suggests no harm from therapy in patients with low baseline pressures, there were so few events (six) in the subgroup of 146 patients with a systolic pressure &lt;120 mmHg at baseline that one cannot have confidence in the results.",
"   </p>",
"   <p>",
"    There was also a suggestion that the risk of recurrent stroke was lowest in patients in the lowest quartile of attained blood pressure (median",
"    <span class=\"nowrap\">",
"     112/72",
"    </span>",
"    mmHg) and progressively higher at higher blood pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the trial was not designed to evaluate different blood pressure goals. (See",
"    <a class=\"local\" href=\"#H1166277\">",
"     'Goal blood pressure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The value of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    -based therapy in the subset of patients in PROGRESS who had atrial fibrillation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39383?source=see_link&amp;anchor=H16#H16\">",
"     \"Stroke in patients with atrial fibrillation\", section on 'Control of hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     PRoFESS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PRoFESS trial (Prevention Regimen for Effectively Avoiding Second Strokes) randomly assigned 20,332 patients with noncardioembolic ischemic stroke to receive either fixed dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    (80 mg daily) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/7\">",
"     7",
"    </a>",
"    ]. All other antihypertensive drugs, except for angiotensin receptor blockers, were permitted as add-on therapy. Approximately three-quarters of patients had a prior history of hypertension, and the average blood pressure was",
"    <span class=\"nowrap\">",
"     144/84",
"    </span>",
"    mmHg in both groups at baseline.",
"   </p>",
"   <p>",
"    At an average follow-up of 2.5 years, there was",
"    <strong>",
"     no",
"    </strong>",
"    significant difference between the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    and placebo groups in the primary outcome of recurrent stroke (8.7 versus 9.2 percent, hazard ratio [HR] 0.95, 95% CI 0.86-1.04), or in secondary outcomes including major cardiovascular events (13.5 versus 14.4 percent, HR 0.94, 95% CI 0.87-1.01). However, significant benefit compared with placebo would not have been expected since telmisartan therapy only reduced the blood pressure by an average",
"    <span class=\"nowrap\">",
"     3.8/2.0",
"    </span>",
"    mmHg more than placebo. This finding is similar to the lack or benefit with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    monotherapy in the PROGRESS trial, in which in the mean difference in attained blood pressure was only",
"    <span class=\"nowrap\">",
"     5/3",
"    </span>",
"    mmHg compared with placebo. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'PROGRESS trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to the fixed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    dose and the fact that most patients in the placebo group received antihypertensive therapy, other factors that could have contributed to the small difference in attained blood pressures in the two groups include cessation of therapy because of side effects in some patients treated with telmisartan, and the initiation of antihypertensive therapy in some patients in the placebo group because of the development of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42645746\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited blood pressure reduction and lack of significant benefit in PRoFESS is important when considering the results of meta-analyses, since PRoFESS was by far the largest study and accounted for more than one-half of patients in the trials of secondary stroke prevention. As illustrated by the following observations, the benefit of antihypertensive therapy increased progressively as the proportion of patients from PRoFESS became smaller:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of eight placebo-controlled trials of angiotensin inhibition included almost 30,000 patients, most of whom came from the PRoFESS trial [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/9\">",
"       9",
"      </a>",
"      ]. Antihypertensive therapy (most of the included trials in this meta-analysis compared angiotensin inhibitors with placebo) resulted in a significant reduction in major cardiovascular events (13.1 versus 14.7 percent, risk ratio 0.92, 95% CI 0.86-0.98) and an almost significant reduction in recurrent stroke (9.0 versus 9.6 percent, risk ratio 0.94, 95% CI 0.87-1.01).",
"     </li>",
"     <li>",
"      The second meta-analysis included 40,300 patients from 16 randomized trials of antihypertensive therapy in patients with a prior stroke, approximately one-half of whom came from PRoFESS [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/5\">",
"       5",
"      </a>",
"      ]. Antihypertensive therapy was associated with a significant reduction in recurrent stroke (relative risk 0.81, 95% CI 0.73-0.91).",
"     </li>",
"     <li>",
"      The third meta-analysis was published in 2003 prior to PRoFESS but including PROGRESS [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/10\">",
"       10",
"      </a>",
"      ] and is the meta-analysis quoted in the 2011",
"      <span class=\"nowrap\">",
"       AHA/ASA",
"      </span>",
"      guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/8\">",
"       8",
"      </a>",
"      ], discussed later. Among seven randomized trials with 15,500 patients, antihypertensive therapy significantly reduced the risk of recurrent stroke (odds ratio 0.76, 95% CI 0.63-0.92). Three trials limited recruitment to patients with hypertension but the other trials recruited patients independent of the presence of hypertension. In most of the trials, the fall in blood pressure compared with placebo was less than",
"      <span class=\"nowrap\">",
"       10/5",
"      </span>",
"      mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     APPROACH TO ANTIHYPERTENSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of questions must be addressed when considering the role of antihypertensive therapy in patients who have had a stroke or transient ischemic attack (TIA):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Which patients should be treated?",
"     </li>",
"     <li>",
"      When should therapy be initiated?",
"     </li>",
"     <li>",
"      Which antihypertensive drugs should be used?",
"     </li>",
"     <li>",
"      What is the goal blood pressure?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the regimen, blood pressure reduction should be gradual. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Gradual blood pressure reduction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90114882\">",
"    <span class=\"h2\">",
"     Which patients should be treated?",
"    </span>",
"    &nbsp;&mdash;&nbsp;With few exceptions, our recommendations are consistent with the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    stroke prevention guidelines that recommend initiation of antihypertensive therapy in",
"    <strong>",
"     all patients",
"    </strong>",
"    who have had an ischemic stroke or TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/8\">",
"     8",
"    </a>",
"    ]. This recommendation is based upon observations in clinical trials, such as PROGRESS, that the relative risk reduction in stroke with antihypertensive therapy was similar at",
"    <strong>",
"     all levels",
"    </strong>",
"    of baseline systolic pressure (ranging from &lt;120 to &ge;160 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients should be advised about signs or symptoms suggesting that the blood pressure may be too low, such as weakness or orthostatic dizziness. (See",
"    <a class=\"local\" href=\"#H420004\">",
"     'AHA/ASA guidelines for the Prevention of Recurrent Stroke'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend antihypertensive therapy in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normotensive patients who have had a stroke or TIA due to a cardioembolic phenomenon (eg, atrial fibrillation) or paradoxical embolus (eg, patent foramen ovale or septal defect).",
"     </li>",
"     <li>",
"      Patients whose initial blood pressure is less than",
"      <span class=\"nowrap\">",
"       120/70",
"      </span>",
"      mmHg. These patients have an increased risk of recurrent stroke compared with patients who have higher blood pressures. (See",
"      <a class=\"local\" href=\"#H3440778\">",
"       'Data from randomized trials'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12986263\">",
"    <span class=\"h2\">",
"     When should therapy be initiated?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of in-hospital initiation or reinitiation of antihypertensive therapy during the acute phase of stroke is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link&amp;anchor=H14#H14\">",
"     \"Initial assessment and management of acute stroke\", section on 'Blood pressure management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who have not been treated in the hospital, antihypertensive therapy should be initiated or reinitiated as an outpatient in all appropriate patients, as noted in the preceding section. (See",
"    <a class=\"local\" href=\"#H90114882\">",
"     'Which patients should be treated?'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12986312\">",
"    <span class=\"h2\">",
"     Which antihypertensive drugs should be used?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our preferences for antihypertensive therapy in patients who have had a stroke or TIA differ according to whether monotherapy or combination antihypertensive therapy is required to achieve an adequate reduction in blood pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15082184\">",
"    <span class=\"h3\">",
"     Monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no compelling evidence favoring one class of antihypertensive drugs over another as monotherapy for secondary prevention in patients who have had a stroke. In a meta-analysis of seven randomized trials of almost 30,000 patients with a prior history of stroke, therapy with angiotensin inhibitors (ACE inhibitors or angiotensin receptor blockers) significantly, but modestly, reduced the risk of recurrent stroke (9.0 versus 9.7 percent) and major vascular events (14.3 versus 15.7 percent) compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, there was no significant benefit of angiotensin inhibitors in the three trials that compared these agents with calcium channel blockers. In addition, calcium channel blockers may be superior to angiotensin inhibitors for the primary prevention of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, both angiotensin inhibitors (most trials have used ACE inhibitors) and calcium channel blockers are reasonable options for initial antihypertensive therapy in patients who have had a stroke. Thiazide diuretics are also commonly used, but data on monotherapy in patients who have had a stroke are limited. There is some evidence from clinical trials that beta blockers may",
"    <strong>",
"     not reduce",
"    </strong>",
"    stroke risk compared with angiotensin inhibitors, calcium channel blockers, and, in some trials, placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Thus, unless there is a compelling indication for their use, beta blockers should",
"    <strong>",
"     not",
"    </strong>",
"    be used for prevention of recurrent stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15082191\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the choice of drugs when combination therapy is necessary. We recommend the combination of an angiotensin inhibitor plus a long-acting dihydropyridine calcium channel blocker. This recommendation contrasts with the 2011",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines that recommend an ACE inhibitor plus a diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H420004\">",
"     'AHA/ASA guidelines for the Prevention of Recurrent Stroke'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines did not mention the ACCOMPLISH trial of combination antihypertensive therapy in hypertensive patients who required two drugs and were at high risk for a cardiovascular event (defined as a history of coronary disease, stroke, peripheral arterial disease, or diabetes or the presence of left ventricular hypertrophy or impaired renal function) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients in ACCOMPLISH were treated with combined therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    and the attained blood pressures were similar in the two groups. History of a prior stroke was present in 13 percent. The trial was terminated early at 36 months because of worse outcomes in the hydrochlorothiazide group that exceeded a prespecified stopping rule. Benazepril plus amlodipine, compared with benazepril plus hydrochlorothiazide, significantly reduced the incidence of the primary endpoint of cardiovascular death or cardiovascular complications (9.6 versus 11.8 percent, hazard ratio [HR] 0.80, 95% CI 0.72-0.90) and the secondary end point of cardiovascular death or nonfatal myocardial infarction or stroke (5.0 versus 6.3 percent, HR 0.79, 95% CI 0.67-0.92).",
"   </p>",
"   <p>",
"    Based upon these observations, we recommend the combination of an",
"    <strong>",
"     angiotensin inhibitor plus a long-acting dihydropyridine calcium channel blocker",
"    </strong>",
"    rather than a diuretic as the combination antihypertensive regimen of choice in the treatment of patients who have had a stroke. This recommendation assumes that the patient can tolerate and does not have a contraindication to the use of either drug class and does not have a specific indication for the use of another class of antihypertensive drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H17#H17\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Indications for specific drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1166277\">",
"    <span class=\"h2\">",
"     Goal blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to goal blood pressure, both in general and specifically in patients with atherosclerotic cardiovascular disease are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This section will review goal blood pressure in patients who have had a stroke or transient ischemic attack (TIA). As will be discussed in greater detail below, the recommendations depend upon whether or not the event was due to a hemodynamically significant stenosis in a large cervicocephalic artery (ie, internal carotid, middle cerebral, vertebral, or basilar artery).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients",
"      <strong>",
"       with",
"      </strong>",
"      hemodynamically significant large artery disease, we suggest cautious blood pressure lowering as tolerated but without a specific blood pressure goal other than a minimum reduction of",
"      <span class=\"nowrap\">",
"       10/5",
"      </span>",
"      mmHg. However, in such patients whose initial blood pressure is less than",
"      <span class=\"nowrap\">",
"       120/70,",
"      </span>",
"      we do not give antihypertensive therapy.",
"     </li>",
"     <li>",
"      In patients",
"      <strong>",
"       without",
"      </strong>",
"      hemodynamically significant large artery stenosis, we take the following approach:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend lowering the blood pressure a minimum of",
"      <span class=\"nowrap\">",
"       10/5",
"      </span>",
"      mmHg in nearly all patients, which is consistent with the recommendations of the",
"      <span class=\"nowrap\">",
"       AHA/ASA",
"      </span>",
"      guidelines. However, in such patients whose initial blood pressure is less than",
"      <span class=\"nowrap\">",
"       120/70,",
"      </span>",
"      we do not give antihypertensive therapy. (See",
"      <a class=\"local\" href=\"#H90114882\">",
"       'Which patients should be treated?'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H420004\">",
"       'AHA/ASA guidelines for the Prevention of Recurrent Stroke'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients with underlying hypertension, we recommend a goal blood pressure of less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg compared with higher pressures and we suggest (a weaker recommendation) lowering the systolic pressure below 130 to 135 mmHg if it can be achieved without producing significant side effects. The evidence supporting this approach in patients with atherosclerotic cardiovascular disease in general is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3440778\">",
"    <span class=\"h3\">",
"     Data from randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of trials, some of which have been cited above, evaluated the relationship between blood pressure and cardiovascular outcomes in patients with a prior stroke. The findings have addressed both the degree of blood pressure reduction from baseline and the absolute level of blood pressure attained, with some differing results.",
"   </p>",
"   <p>",
"    A major limitation is that",
"    <strong>",
"     none",
"    </strong>",
"    of the following trials except for ACCORD BP was specifically designed to determine the optimal goal blood pressure. Prospective randomized trials evaluating intensive versus usual blood pressure control to prevent recurrent stroke have",
"    <strong>",
"     not",
"    </strong>",
"    been performed.",
"   </p>",
"   <p>",
"    The following observations suggest that lower blood pressures are associated with better outcomes but causality cannot be proven with the exception of ACCORD BP. Analyses according to the presence or absence of a large cervicocephalic artery stenosis were not performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-regression analysis of nine randomized trials found that each 10 mmHg reduction in systolic pressure was associated with a 33 percent (95% CI 9 to 51 percent) reduction in the risk of recurrent stroke, with the lowest risk occurring at an attained systolic pressure below 120 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar findings were noted a review from the United Kingdom Transient Ischemic Attack trial: there was a 28 percent reduction in recurrent stroke for every 10 mmHg reduction in systolic pressure and a 34 percent reduction for every 5 mmHg reduction in diastolic pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the PROGRESS trial, the risk of recurrent stroke was lowest in patients in the lowest quartile of attained blood pressure (median",
"      <span class=\"nowrap\">",
"       112/72",
"      </span>",
"      mmHg) and progressively higher at higher blood pressures [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'PROGRESS trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a meta-analysis of 25 randomized trials of antihypertensive therapy versus placebo in patients with a history of cardiovascular disease without hypertension, the treated patients had significantly better cardiovascular outcomes including reductions in cardiovascular events (relative risk 0.77, 95% CI 0.61-0.98), cardiovascular mortality (relative risk 0.83, 95% CI 0.69-0.99), and stroke (relative risk, 0.80, 95% CI 0.69-0.93) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/17\">",
"       17",
"      </a>",
"      ]. The absolute reduction in stroke risk was 7.7 per 1000 persons.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations are consistent with the findings in the ACCORD BP trial of 4733 patients with type 2 diabetes plus other cardiovascular risk factors; prior stroke was uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/18\">",
"     18",
"    </a>",
"    ]. The patients were randomly assigned to a goal systolic pressure of less than 140 or less than 120 mmHg and the mean attained systolic pressures were 134 and 119 mmHg, respectively. At a mean follow-up of 4.7 years, there was no overall cardiovascular benefit of lowering the systolic pressure below 120 mmHg but, on subset analysis, there was a small but significant reduction in the annual rate of stroke (0.32 versus 0.53 percent, hazard ratio 0.59). More aggressive therapy was also associated with significantly higher rate of serious adverse effects attributable to antihypertensive drugs (3.3 versus 1.3 percent).",
"   </p>",
"   <p>",
"    In contrast to these observations,",
"    <strong>",
"     harm",
"    </strong>",
"    rather than benefit from an attained systolic pressure below 120 mmHg was noted an analysis from the PRoFESS trial cited above (by far the largest trial) in which the average reduction in blood pressure with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    therapy was only",
"    <span class=\"nowrap\">",
"     3.8/2.0",
"    </span>",
"    mmHg more than with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'PRoFESS trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    At a mean follow-up of 2.5 years, patients with a post-baseline mean systolic pressure of 130 to 139 mmHg had the lowest rate of recurrent stroke and the lowest rate of a composite outcome of stroke, myocardial infarction, or vascular death. Patients with a mean systolic pressure of 120 to 129 mmHg had slightly but nonsignificantly higher rates of recurrent stroke, while the risk of recurrent stroke was significantly",
"    <strong>",
"     increased",
"    </strong>",
"    in patients with mean systolic blood pressures of less than 120 mmHg systolic (adjusted hazard ratio 1.29, 95% CI 1.07-1.56), 140 to 149 mmHg systolic (adjusted hazard ratio 1.23), and &ge;150 mmHg systolic (adjusted hazard ratio 2.08). The same groups had a similar increase in risk for the composite end point of stroke, myocardial infarction, or vascular death.",
"   </p>",
"   <p>",
"    As discussed in the following sections, the goal blood pressure depends upon whether or not the patient has hemodynamically significant large artery stenosis, which some have defined on imaging studies as &ge;80 percent stenosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    poor collateral flow (if it can be detected). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"     \"Evaluation of carotid artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1166386\">",
"    <span class=\"h3\">",
"     Patients with hemodynamically significant large artery stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying hemodynamically or clinically significant stenosis in a large cervicocephalic artery (internal carotid, middle cerebral, vertebral, or basilar artery) is important clinically since these patients have an increased long-term risk of recurrent stroke and may develop",
"    <strong>",
"     ischemic symptoms after blood pressure lowering",
"    </strong>",
"    . This was illustrated in a study of 102 patients who had a history of ischemic stroke of transient ischemic attack (TIA) and a large artery stenosis of 50 percent or more [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/20\">",
"     20",
"    </a>",
"    ]. Hemodynamically significant was defined clinically as the occurrence of symptoms related to the stenosis during a change of position from supine to prone, following effort, or after the introduction or increase in dose of an antihypertensive drug. The rate of recurrent stroke or TIA in the territory of the stenotic artery at two years was 61 percent in patients with a hemodynamically significant stenosis compared with 32 percent in patients without a significant stenosis. &nbsp;",
"   </p>",
"   <p>",
"    There is no consensus regarding the criteria for defining hemodynamically significant stenosis. In addition to the clinical criteria used in the preceding study, some have used criteria based upon imaging studies. As an example, we have used the following criteria: &ge;80 percent stenosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    poor collateral flow (if collateral flow can be detected). Others have used parameters such as cerebral blood volume and oxygen extraction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another problem is that, even in patients at increased risk, there is currently no reliable method of determining which patients can safely tolerate intensive blood pressure lowering.",
"   </p>",
"   <p>",
"    In summary, in patients thought to have a hemodynamically significant stenosis of a large cervicocerebral artery based upon one or more of the above criteria, we suggest cautious blood pressure lowering as tolerated but without a specific blood pressure goal other than a minimum reduction of",
"    <span class=\"nowrap\">",
"     10/5",
"    </span>",
"    mmHg below the previous baseline, a recommendation consistent with those made in the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines. (See",
"    <a class=\"local\" href=\"#H420004\">",
"     'AHA/ASA guidelines for the Prevention of Recurrent Stroke'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The patient should be carefully monitored for hypotensive or neurologic symptoms caused by either failure of autoregulation of cerebral blood flow or by hemodynamic compromise due to large vessel stenosis. If the patient develops recurrent neurologic symptoms referable to a stenotic artery when the blood pressure is lowered below a particular threshold, we recommend management to maintain blood pressure above that threshold. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Gradual blood pressure reduction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If a hemodynamically significant stenosis of an extracranial carotid artery is corrected by endarterectomy or stenting, we attempt to gradually achieve the blood pressure goals described in the following section on patients without hemodynamically significant large artery stenosis in order to reduce the risks of recurrent stroke and other cardiovascular events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H214712420\">",
"    <span class=\"h3\">",
"     Patients without hemodynamically significant large artery stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have had a stroke or transient ischemic attack that did",
"    <strong>",
"     not",
"    </strong>",
"    result from a hemodynamically significant large cervicocephalic artery stenosis as defined in the preceding paragraph, our recommendations for goal blood pressure are similar to those in other patients with atherosclerotic cardiovascular disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend lowering the blood pressure a minimum of",
"      <span class=\"nowrap\">",
"       10/5",
"      </span>",
"      mmHg in all patients, which is consistent with the recommendations of the",
"      <span class=\"nowrap\">",
"       AHA/ASA",
"      </span>",
"      guidelines. However, in such patients whose initial blood pressure is less than",
"      <span class=\"nowrap\">",
"       120/70,",
"      </span>",
"      we do not give antihypertensive therapy. (See",
"      <a class=\"local\" href=\"#H420004\">",
"       'AHA/ASA guidelines for the Prevention of Recurrent Stroke'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients with underlying hypertension, we recommend a goal blood pressure of less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg compared with higher pressures and we suggest (a weaker recommendation) lowering the systolic pressure below 130 to 135 mmHg if it can be achieved without producing significant side effects. The evidence supporting this approach in patients with atherosclerotic cardiovascular disease in general is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gradual blood pressure reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal response to an acute reduction in BP is to maintain tissue perfusion by autoregulatory precapillary vasodilation. Since flow is equal to pressure divided by resistance, parallel reductions in both parameters allows flow to be maintained. This response may be impaired in patients with chronic hypertension, including those who have not had a stroke.",
"   </p>",
"   <p>",
"    Persistent hypertension leads to arteriolar thickening. In the cerebral and other circulations, this is in part an",
"    <strong>",
"     appropriate",
"    </strong>",
"    adaptation in that it prevents the increase in pressure from being transmitted to the capillary circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, arteriolar thickening can also limit the ability to maintain perfusion when the blood pressure is lowered with antihypertensive therapy, since the vasodilator response is often impaired. As a result, the lower blood pressure limit at which cerebral perfusion is maintained is higher in hypertensive than in normotensive subjects (",
"    <a class=\"graphic graphic_figure graphicRef57676 \" href=\"UTD.htm?33/13/34013\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/22\">",
"     22",
"    </a>",
"    ]. In general, ischemic symptoms are not likely to occur unless the BP is acutely reduced by more than 25 percent below the baseline level.",
"   </p>",
"   <p>",
"    Based upon these concerns, gradual BP reduction is recommended in patients with known cerebrovascular disease or long-standing uncontrolled hypertension unless there is a hypertensive emergency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=see_link\">",
"     \"Treatment of specific hypertensive emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420004\">",
"    <span class=\"h1\">",
"     AHA/ASA GUIDELINES FOR THE PREVENTION OF RECURRENT STROKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the prevention of recurrent stroke and other vascular events issued in 2011 by the American Heart Association and American Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA)",
"    </span>",
"    recommend antihypertensive treatment for",
"    <strong>",
"     all patients",
"    </strong>",
"    (ie, with and without hypertension) with ischemic stroke or transient ischemic attack (TIA) who are considered appropriate for such therapy in an attempt to prevent recurrent stroke and other vascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with this recommendation",
"    <strong>",
"     except",
"    </strong>",
"    in the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normotensive patients whose stroke or TIA was due to a cardioembolic phenomenon (eg, atrial fibrillation) or a paradoxical embolus (eg, venous thrombosis in someone with a patent foramen ovale). Although there are no data, we do",
"      <strong>",
"       not",
"      </strong>",
"      recommend antihypertensive therapy in such patients.",
"     </li>",
"     <li>",
"      Patients whose initial blood pressure is",
"      <span class=\"nowrap\">",
"       120/70",
"      </span>",
"      mmHg or less. Achieved blood pressures below this level were associated with a higher risk of recurrent stroke in the PRoFESS trial, as discussed below. Thus, we do",
"      <strong>",
"       not",
"      </strong>",
"      recommend antihypertensive therapy in such patients whose initial blood pressure is below",
"      <span class=\"nowrap\">",
"       120/70",
"      </span>",
"      mmHg. (See",
"      <a class=\"local\" href=\"#H3440778\">",
"       'Data from randomized trials'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    made the following additional comments about long-term antihypertensive therapy to prevent recurrent stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17305/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The target blood pressure level and degree of reduction are uncertain, and treatment should be individualized. Benefit has been associated with an average blood pressure reduction of approximately 10 mmHg systolic and 5 mmHg diastolic. (See",
"      <a class=\"local\" href=\"#H1166277\">",
"       'Goal blood pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lifestyle modifications that have been associated with blood pressure reductions should be included as part of the antihypertensive regimen. Important modifications include weight loss, salt restriction, a diet rich in fruits, vegetables, and low-fat dairy products, regular aerobic physical activity, and limited alcohol consumption. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link&amp;anchor=H27#H27\">",
"       \"Overview of hypertension in adults\", section on 'Nonpharmacologic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The optimal antihypertensive drug regimen is uncertain but the available data indicate that diuretics or the combination of diuretics and an ACE inhibitor are useful. The choice of specific drugs should be individualized with respect to patient characteristics such as extracranial cerebrovascular occlusive disease, renal impairment, cardiac disease, and diabetes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We",
"    <strong>",
"     disagree",
"    </strong>",
"    with the recommendation for combined therapy with diuretics and an angiotensin inhibitor. Our reasons for disagreeing with the",
"    <span class=\"nowrap\">",
"     AHS/ASA",
"    </span>",
"    guidelines and our preference for combination antihypertensive therapy are discussed in detail above. (See",
"    <a class=\"local\" href=\"#H15082191\">",
"     'Combination therapy'",
"    </a>",
"    above.)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       \"Patient information: Stroke (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/37/36435?source=see_link\">",
"       \"Patient information: Medicines after an ischemic stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27432801\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of hypertension may be an immediate concern in patients with an acute ischemic stroke and those with a subarachnoid or intracerebral hemorrhage. Blood pressure management in the acute phase of stroke is different from chronic therapy and is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link&amp;anchor=H14#H14\">",
"       \"Initial assessment and management of acute stroke\", section on 'Blood pressure management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H18#H18\">",
"       \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Blood pressure control'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Intracranial pressure and blood pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Once the stroke has stabilized, antihypertensive therapy can reduce the rate of recurrent stroke, independent of the baseline blood pressure. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Trials of long-term antihypertensive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The target blood pressure level and degree of reduction are uncertain, and treatment should be individualized. Benefit has been associated with an average blood pressure reduction of approximately 10 mmHg systolic and 5 mmHg diastolic. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'PROGRESS trial'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H420004\">",
"       'AHA/ASA guidelines for the Prevention of Recurrent Stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lifestyle modifications that have been associated with blood pressure reductions should be included as part of the antihypertensive regimen. Important modifications include weight loss, salt restriction, a diet rich in fruits, vegetables, and low-fat dairy products, regular aerobic physical activity, and limited alcohol consumption. (See",
"      <a class=\"local\" href=\"#H420004\">",
"       'AHA/ASA guidelines for the Prevention of Recurrent Stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We generally agree with the",
"      <span class=\"nowrap\">",
"       AHA/ASA",
"      </span>",
"      stroke prevention guidelines that recommend initiation of antihypertensive therapy in all patients who have had an ischemic stroke or TIA. However, we do",
"      <strong>",
"       not",
"      </strong>",
"      recommend antihypertensive therapy in the following settings (see",
"      <a class=\"local\" href=\"#H90114882\">",
"       'Which patients should be treated?'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Normotensive patients who have had a stroke or TIA due to a cardioembolic phenomenon (eg, atrial fibrillation) or paradoxical embolus (eg, patent foramen ovale or septal defect).",
"     </li>",
"     <li>",
"      Patients whose initial blood pressure is less than",
"      <span class=\"nowrap\">",
"       120/70",
"      </span>",
"      mmHg. These patients have an increased risk of recurrent stroke compared with patients who have higher blood pressures. (See",
"      <a class=\"local\" href=\"#H3440778\">",
"       'Data from randomized trials'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The timing of in-hospital initiation or reinitiation of antihypertensive therapy during the acute phase of stroke is discussed in detail elsewhere. For patients who have not been treated in the hospital, antihypertensive therapy should be initiated or reinitiated as an outpatient in all appropriate patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link&amp;anchor=H14#H14\">",
"       \"Initial assessment and management of acute stroke\", section on 'Blood pressure management'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H12986263\">",
"       'When should therapy be initiated?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our preferences for antihypertensive therapy in patients who have had a stroke or TIA differ according to whether monotherapy or combination antihypertensive therapy is required to achieve an adequate reduction in blood pressure (see",
"      <a class=\"local\" href=\"#H12986312\">",
"       'Which antihypertensive drugs should be used?'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There is no compelling evidence favoring one class of antihypertensive drugs over another as",
"      <strong>",
"       monotherapy",
"      </strong>",
"      for secondary prevention in patients who have had a stroke. Both angiotensin inhibitors (most trials have used ACE inhibitors) and calcium channel blockers are reasonable options for initial antihypertensive monotherapy in such patients. Thiazide diuretics are also commonly used, but data on monotherapy in patients who have had a stroke are limited. Unless there is a compelling indication for their use, beta blockers should",
"      <strong>",
"       not",
"      </strong>",
"      be used for prevention of recurrent stroke. (See",
"      <a class=\"local\" href=\"#H15082184\">",
"       'Monotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We disagree with the 2011",
"      <span class=\"nowrap\">",
"       AHA/ASA",
"      </span>",
"      guidelines that recommend an ACE inhibitor plus a diuretic for patients who have had a stroke or TIA and require",
"      <strong>",
"       combination antihypertensive therapy",
"      </strong>",
"      . Based upon observations from the ACCOMPLISH trial, we recommend the combination of an angiotensin inhibitor plus a long-acting dihydropyridine calcium channel blocker rather than a diuretic as the combination antihypertensive regimen of choice in the treatment of patients who have had a stroke. This recommendation assumes that the patient can tolerate and does not have a contraindication to the use of either drug class and does not have a specific indication for the use of another class of antihypertensive drugs. (See",
"      <a class=\"local\" href=\"#H15082191\">",
"       'Combination therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Our recommendations for goal blood pressure in patients who have had a stroke or TIA depend upon whether or not the event was due to a hemodynamically significant stenosis in a large cervicocephalic artery (ie, internal carotid, middle cerebral, vertebral, or basilar artery) (see",
"      <a class=\"local\" href=\"#H1166277\">",
"       'Goal blood pressure'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients",
"      <strong>",
"       with",
"      </strong>",
"      hemodynamically significant large artery disease, we suggest cautious blood pressure lowering as tolerated but without a specific blood pressure goal other than a minimum reduction of",
"      <span class=\"nowrap\">",
"       10/5",
"      </span>",
"      mmHg. However, in such patients whose initial blood pressure is less than",
"      <span class=\"nowrap\">",
"       120/70,",
"      </span>",
"      we do not give antihypertensive therapy. (See",
"      <a class=\"local\" href=\"#H1166386\">",
"       'Patients with hemodynamically significant large artery stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients",
"      <strong>",
"       without",
"      </strong>",
"      hemodynamically significant large artery stenosis, we take the following approach (see",
"      <a class=\"local\" href=\"#H214712420\">",
"       'Patients without hemodynamically significant large artery stenosis'",
"      </a>",
"      above):",
"      <br/>",
"      <br/>",
"      We recommend lowering the blood pressure a minimum of",
"      <span class=\"nowrap\">",
"       10/5",
"      </span>",
"      mmHg in nearly all patients, which is consistent with the recommendations of the",
"      <span class=\"nowrap\">",
"       AHA/ASA",
"      </span>",
"      guidelines. However, in such patients whose initial blood pressure is less than",
"      <span class=\"nowrap\">",
"       120/70,",
"      </span>",
"      we do not give antihypertensive therapy.",
"      <br/>",
"      <br/>",
"      In patients with underlying hypertension, we recommend a goal blood pressure of less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg compared with higher pressures and we suggest (a weaker recommendation) lowering the systolic pressure below 130 to 135 mmHg if it can be achieved without producing significant side effects. The evidence supporting this approach in patients with atherosclerotic cardiovascular disease in general is discussed in detail elsewhere. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with hemodynamically significant large artery disease who are given antihypertensive therapy, the patient should be carefully monitored for hypotensive or neurologic symptoms caused by either failure of autoregulation of cerebral blood flow or by hemodynamic compromise due to large vessel stenosis. If the patient develops recurrent neurologic symptoms referable to a stenotic artery when the blood pressure is lowered below a particular threshold, we recommend management to maintain blood pressure above that threshold. (See",
"      <a class=\"local\" href=\"#H1166386\">",
"       'Patients with hemodynamically significant large artery stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a hemodynamically significant stenosis of an extracranial carotid artery is corrected by endarterectomy or stenting, we attempt to gradually achieve the blood pressure goals described in the following section on patients without hemodynamically significant large artery stenosis in order to reduce the risks of recurrent stroke and other cardiovascular events. (See",
"      <a class=\"local\" href=\"#H1166386\">",
"       'Patients with hemodynamically significant large artery stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regardless of the regimen, blood pressure reduction should be gradual. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Gradual blood pressure reduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/1\">",
"      Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/2\">",
"      Messerli FH, Bangalore S. Blood pressure and stroke: findings from recent trials. J Am Coll Cardiol 2011; 57:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/3\">",
"      Rothwell PM, Algra A, Amarenco P. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet 2011; 377:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/4\">",
"      PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/5\">",
"      Arima H, Chalmers J. PROGRESS: Prevention of Recurrent Stroke. J Clin Hypertens (Greenwich) 2011; 13:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/6\">",
"      Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006; 24:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/7\">",
"      Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/8\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/9\">",
"      Lee M, Saver JL, Hong KS, et al. Renin-Angiotensin system modulators modestly reduce vascular risk in persons with prior stroke. Stroke 2012; 43:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/10\">",
"      Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003; 34:2741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/11\">",
"      Chen N, Zhou M, Yang M, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev 2010; :CD003654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/12\">",
"      Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007; :CD002003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/13\">",
"      Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007; 100:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/14\">",
"      Bangalore S, Wild D, Parkar S, et al. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol 2008; 52:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/15\">",
"      Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/16\">",
"      Rodgers A, MacMahon S, Gamble G, et al. Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group. BMJ 1996; 313:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/17\">",
"      Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 2011; 305:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/18\">",
"      ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/19\">",
"      Ovbiagele B, Diener HC, Yusuf S, et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 2011; 306:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/20\">",
"      Mazighi M, Tanasescu R, Ducrocq X, et al. Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurology 2006; 66:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/21\">",
"      Derdeyn CP, Videen TO, Yundt KD, et al. Variability of cerebral blood volume and oxygen extraction: stages of cerebral haemodynamic impairment revisited. Brain 2002; 125:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17305/abstract/22\">",
"      Strandgaard S, Olesen J, Skinhoj E, Lassen NA. Autoregulation of brain circulation in severe arterial hypertension. Br Med J 1973; 1:507.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3823 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17305=[""].join("\n");
var outline_f16_57_17305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27432801\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRIALS OF LONG-TERM ANTIHYPERTENSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROGRESS trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PRoFESS trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42645746\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      APPROACH TO ANTIHYPERTENSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90114882\">",
"      Which patients should be treated?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12986263\">",
"      When should therapy be initiated?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12986312\">",
"      Which antihypertensive drugs should be used?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15082184\">",
"      - Monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15082191\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1166277\">",
"      Goal blood pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3440778\">",
"      - Data from randomized trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1166386\">",
"      - Patients with hemodynamically significant large artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H214712420\">",
"      - Patients without hemodynamically significant large artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gradual blood pressure reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H420004\">",
"      AHA/ASA GUIDELINES FOR THE PREVENTION OF RECURRENT STROKE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27432801\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3823\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3823|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/13/34013\" title=\"figure 1\">",
"      Cerebral autoregulation in hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=related_link\">",
"      Evaluation of carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/37/36435?source=related_link\">",
"      Patient information: Medicines after an ischemic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39383?source=related_link\">",
"      Stroke in patients with atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=related_link\">",
"      Treatment of specific hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_57_17306="Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat";
var content_f16_57_17306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/57/17306/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/57/17306/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/57/17306/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/57/17306/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/57/17306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/57/17306/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/57/17306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia in the syndrome of inappropriate antidiuretic hormone secretion (SIADH) results from ADH-induced retention of ingested or infused water. Although water excretion is impaired, sodium handling is intact, since there is no abnormality in volume-regulating mechanisms such as the renin-angiotensin-aldosterone system or atrial natriuretic peptide [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of hyponatremia due to SIADH (including the reset osmostat variant) will be reviewed here. The choice of therapy of SIADH is dependent upon a number of factors including the degree of hyponatremia, the presence or absence of symptoms, and, to some degree, the urine osmolality.",
"   </p>",
"   <p>",
"    The pathogenesis and etiology of the SIADH and a general review of the treatment of hyponatremia due to a variety of causes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link\">",
"     \"Overview of the treatment of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To understand the approach to therapy of hyponatremia in SIADH, it is worthwhile to briefly review the pathogenesis of hyponatremia in this disorder. Among patients with SIADH, the combination of water retention and secondary solute (sodium plus potassium) loss accounts for essentially all of the reduction in serum sodium [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These changes occur in the following sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyponatremia is initially mediated by ADH-induced water retention.",
"     </li>",
"     <li>",
"      The ensuing volume expansion activates secondary natriuretic mechanisms, resulting in sodium and water loss and the restoration of near euvolemia. The net effect is that, with chronic SIADH, sodium loss is more prominent than water retention [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/3\">",
"       3",
"      </a>",
"      ]. However, since there is no impairment in volume regulatory hormones (aldosterone and natriuretic peptides), patients with SIADH are",
"      <strong>",
"       euvolemic",
"      </strong>",
"      unless there is a second problem leading to salt loss (eg, vomiting, diarrhea, or diuretic therapy).",
"     </li>",
"     <li>",
"      Hyponatremia may also be associated with potassium loss. Since potassium is as osmotically active as sodium, the loss of potassium contributes to the reductions in plasma osmolality and sodium concentration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of the treatment of hyponatremia\", section on 'Effect of potassium'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lost potassium is derived from the cells and probably represents part of the cell's volume regulatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/3\">",
"     3",
"    </a>",
"    ]. Cells that increase in size due to water entry in hyponatremia lose potassium and other solutes in an attempt to restore cell volume. This adaptation is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H4#H4\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Osmolytes and cerebral adaptation to hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THERAPIES TO RAISE THE SERUM SODIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of modalities can be used to correct hyponatremia in the SIADH, with fluid restriction, salt administration, and vasopressin receptor antagonists being most important [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. When treating such patients, attention must be paid to the rate of correction.",
"   </p>",
"   <p>",
"    There are three components to the treatment of hyponatremia in SIADH:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment of the underlying disease, if possible",
"     </li>",
"     <li>",
"      Initial therapy to raise the serum sodium",
"     </li>",
"     <li>",
"      Prolonged therapy in patients with persistent SIADH",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treat the underlying disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of causes of SIADH can be effectively treated, leading to resolution of the hyponatremia. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hormone replacement in adrenal insufficiency (which can lead to overly rapid correction of the hyponatremia) or hypothyroidism",
"     </li>",
"     <li>",
"      Treatment of infections such as meningitis, pneumonia, or tuberculosis",
"     </li>",
"     <li>",
"      Cessation of offending drugs, such as selective serotonin reuptake inhibitors or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"       chlorpropamide",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fluid restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid restriction is a mainstay of therapy in most patients with SIADH, with a suggested goal intake of less than 800",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/4\">",
"     4",
"    </a>",
"    ]. The associated negative water balance initially raises the serum sodium concentration toward normal and, with maintenance therapy in chronic SIADH, prevents a further reduction in serum sodium. It can also lead to volume depletion due to unmasking of the sodium deficit described above unless sodium intake is also adequate. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Subarachnoid hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid restriction may not be appropriate for hyponatremia associated with subarachnoid hemorrhage (SAH). Patients with SAH are at risk for cerebral vasospasm and infarction, the incidence of which is increased by a fall in blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/7\">",
"     7",
"    </a>",
"    ]. Because of the neurologic symptoms associated with the cerebral bleeding, it is typically difficult to determine the role, if any, of the hyponatremia in the pathogenesis of the symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyponatremia in patients with SAH is usually due to SIADH, but is often inappropriately characterized as cerebral salt-wasting (CSW), a much less common problem [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/8\">",
"     8",
"    </a>",
"    ]. The two disorders have similar manifestations, and it is only the presence of clear evidence of volume depletion (eg, hypotension, decreased skin turgor, possibly increased blood urea",
"    <span class=\"nowrap\">",
"     nitrogen/serum",
"    </span>",
"    creatinine ratio) despite a urine sodium concentration that is not low that suggests that CSW might be present rather than SIADH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8567?source=see_link\">",
"     \"Cerebral salt-wasting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluid restriction is a standard component of therapy in SIADH, but may promote cerebral vasospasm in patients with SAH who are usually treated with volume expansion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Prevention of vasospasm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, hyponatremic patients with SAH should be treated with hypertonic (3 percent) saline to both preserve cerebral perfusion and prevent complications from hyponatremia-induced brain swelling. One proposed regimen is an initial infusion rate of 20",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    with subsequent dosing being dependent upon serial measurements of serum sodium at six hour intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/9\">",
"     9",
"    </a>",
"    ]. Fluid therapy in normonatremic patients with SAH is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8567?source=see_link&amp;anchor=H10#H10\">",
"     \"Cerebral salt-wasting\", section on 'Therapy of SIADH associated with SAH'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Intravenous saline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe, symptomatic, or resistant hyponatremia in patients with SIADH often requires the administration of sodium chloride. If the serum sodium concentration is to be elevated, the electrolyte concentration of the fluid given must",
"    <strong>",
"     exceed the electrolyte concentration of the urine",
"    </strong>",
"    , not simply that of the plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The calculations that follow are similar to those that are described in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the treatment of hyponatremia\", section on 'SIADH'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The calculations are based upon two important physiologic principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sodium and water excretion in the urine are regulated independently: sodium by aldosterone and atrial natriuretic peptide; and water by ADH.",
"     </li>",
"     <li>",
"      The urine volume is normally regulated by ADH in response to changes in water intake. When ADH release does not respond to changes in water intake, as usually occurs in SIADH, the urine osmolality is relatively fixed and the urine volume varies with changes in solute excretion. Increasing solute excretion by giving salt or urea will increase the urine volume and tend to raise the serum sodium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect of isotonic saline in patients with SIADH can be illustrated by a simple example. Suppose a patient with SIADH has a serum sodium of 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and a urine osmolality that is relatively fixed at 616",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    If 1000 mL of isotonic saline is given (containing 154 meq each of Na and Cl or 308 mosmol), the serum sodium will initially rise (by about 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    per liter of isotonic saline) because isotonic saline has a higher sodium concentration than the patient's serum. However, all of the sodium chloride will be excreted (because sodium handling is intact in SIADH) but in only 500 mL of water (308 mosmol in 500 mL of water equals 616",
"    <span class=\"nowrap\">",
"     mosmol/kg).",
"    </span>",
"    The excretion of all of administered saline with retention of one-half of the administered water will worsen the hyponatremia.",
"   </p>",
"   <p>",
"    This hypothetical example has been confirmed in postoperative patients, many of whom have transient SIADH. In one report, for example, the administration of isotonic saline or lactated Ringer's solution to 22 women who had undergone uncomplicated gynecologic surgery resulted in a fall in the serum sodium concentration by a mean of 4.2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 21 of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/10\">",
"     10",
"    </a>",
"    ]. During the first 16 hours after the induction of anesthesia, the mean peak urine osmolality was more than 600",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    and the mean urinary sodium plus potassium concentration was almost 300",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (twice that in plasma). The loss of sodium plus potassium in the urine at a much higher concentration than in the plasma was responsible for the fall in serum sodium.",
"   </p>",
"   <p>",
"    The response is different if hypertonic saline is given. Each liter of 3 percent saline contains 1026 mosmol (513 meq each of sodium and chloride). If 500 mL of this solution (which contains 257 meq of sodium) is slowly given to a 60 kg woman with a total body water of approximately 30 liters and a baseline serum sodium of 120",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    the extra 257 meq of sodium will distribute over 30.5 liters, raising the serum sodium by 6.5",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    The rise in serum sodium after 500 mL of hypertonic saline will be smaller in a 70 kg man who has a larger total body water of approximately 42 liters. In this setting, the extra 257 meq of sodium will distribute over 42.5 liters, raising the serum sodium by 4.6",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p>",
"    However, the rise in serum sodium in response to 3 percent saline will partially dissipate over time, because all of the sodium chloride will be excreted (as with isotonic saline), but in a larger volume of approximately 830 mL (513 mosmol at a urine osmolality of 616",
"    <span class=\"nowrap\">",
"     mosmol/kg).",
"    </span>",
"    The net effect is that sodium chloride balance is unchanged but 330 mL of fluid have been lost, which will result in final elevation in the serum sodium of only 1.3",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in a 60 kg woman (120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at baseline x",
"    <span class=\"nowrap\">",
"     [30/29.67])",
"    </span>",
"    and 1.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in a 70 kg man (120 x",
"    <span class=\"nowrap\">",
"     [42/41.67]).",
"    </span>",
"   </p>",
"   <p>",
"    Thus, after the administration of hypertonic saline in a hyponatremic patient with a high urine osmolality, there will be an initial large rise in the serum sodium concentration that falls over time as the administered sodium is excreted.",
"   </p>",
"   <p>",
"    The late reduction in serum sodium is less pronounced (ie, there is a greater persistent elevation in serum sodium) if the urine osmolality is not so high since more water will follow the excretion of sodium chloride. If, for example, the urine osmolality is 300 not 616",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    then the 513 mosmol of sodium chloride will be excreted in 1710 mL of urine. Thus, the net fluid loss will be 1210 mL (1710 minus 500 mL given), resulting in a final elevation in serum sodium of 5.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in a 60 kg woman (120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at baseline x",
"    <span class=\"nowrap\">",
"     [30/28.8])",
"    </span>",
"    and 3.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in a 70 kg man (120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at baseline x",
"    <span class=\"nowrap\">",
"     [42/40.8])",
"    </span>",
"   </p>",
"   <p>",
"    These calculations illustrate the limited long-term effect of even hypertonic saline in hyponatremic patients with SIADH who have a highly concentrated urine. Thus, in addition to restricting water intake, efforts must also be made in such patients to reduce the urinary concentration (ie, lower the urine osmolality), which can be achieved with a loop diuretic or a vasopressin receptor antagonist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H155108392\">",
"    <span class=\"h2\">",
"     High solute intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal individuals, the urine output is primarily determined by fluid intake, a relationship that is mediated by changes in the release of antidiuretic hormone that lead to appropriate changes in the urine osmolality. However, when the urine osmolality is fixed, as in SIADH, the urine output is determined by the intake and subsequent urinary excretion of solutes (mostly sodium salts and urea), which has been called the renal solute load. As an example, at a fixed urine osmolality of 600",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in a patient with SIADH, the urine output will be 1",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    if urinary solute excretion in 600",
"    <span class=\"nowrap\">",
"     mosmol/day",
"    </span>",
"    and 2",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    if urinary solute excretion is increased to 1200",
"    <span class=\"nowrap\">",
"     mosmol/day",
"    </span>",
"    by a high sodium, high protein diet or with the ingestion of salt",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urea tablets. Such a high solute diet can be combined with a loop diuretic, which interferes with concentrating ability and lowers the urine osmolality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Oral salt tablets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles described in the above section on intravenous saline also apply to oral salt intake. Suppose the same 60 kg woman with a serum sodium of 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and total body water of approximately 30 L takes in 9 g of salt (154 meq each of sodium and chloride) in tablet form. All 308 mosmol will be excreted, since sodium handling is normal, which will increase the urine output by 500 mL if the urine osmolality is 616",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    and by approximately 1000 mL if the urine osmolality is 308",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    Using the calculations in the above section, this extra loss of water will tend to raise the serum sodium by 2.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at baseline x",
"    <span class=\"nowrap\">",
"     [30/29.5])",
"    </span>",
"    if the urine osmolality is 616",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    and by 4.1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at baseline x",
"    <span class=\"nowrap\">",
"     [30/29])",
"    </span>",
"    if the urine osmolality is 308",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Intravenous saline'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some patients with chronic SIADH have a major underlying illness (such as small cell carcinoma) that may limit compliance with increased dietary salt intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Salt plus a loop diuretic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of salt tablets (as with hypertonic saline) can be enhanced if given with a drug that lowers the urine osmolality and increases water excretion. This can be achieved by impairing the renal responsiveness to ADH by the administration of a loop diuretic or a vasopressin receptor antagonist. A loop diuretic (eg, 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    orally twice a day) directly interferes with the countercurrent concentrating mechanism by decreasing sodium chloride reabsorption in the medullary aspect of the loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A loop diuretic will be effective if the urine osmolality is more than twice the plasma osmolality, which typically means a urine osmolality above 500",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    Monitoring of the serum potassium is important, particularly in the early stages of therapy. Some patients require",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    supplementation or use of a potassium-sparing diuretic, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Urea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another way to increase urinary solute excretion and enhance water excretion in patients with SIADH is the administration of urea, usually at a dose of 30",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This regimen is reported to be generally well tolerated, and has been used chronically in ambulatory patients. However, it is seldom used in the United States because urea is not readily available in pharmacies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vasopressin receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three receptors for vasopressin (ADH): the V1a, V1b, and V2 receptors. The V2 receptors primarily mediate the antidiuretic response, while V1a and V1b receptors primarily cause vasoconstriction and adrenocorticotropic hormone (ACTH) release, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vasopressin receptor antagonists produce a selective water diuresis (aquaresis) without affecting sodium and potassium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The ensuing loss of electrolyte-free water will tend to raise the serum sodium in patients with SIADH and may improve mental status in patients with a serum sodium under 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/17\">",
"     17",
"    </a>",
"    ]. Thirst increases significantly with these agents, which may limit the rise in serum sodium [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the treatment of hyponatremia\", section on 'Vasopressin receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some oral formulations&mdash;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    , mozavaptan, satavaptan, and lixivaptan&mdash;are selective for the V2 receptor, while an intravenous agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"     conivaptan",
"    </a>",
"    , blocks both the V2 and V1a receptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized double-blind trials have shown that oral or intravenous vasopressin antagonists (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    , lixivaptan, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"     conivaptan",
"    </a>",
"    ) are more effective than placebo in raising the serum sodium of hyponatremic patients both in and out of the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/17-23\">",
"     17-23",
"    </a>",
"    ]. Most of the patients studied in these trials had asymptomatic or mildly symptomatic hyponatremia and an average serum sodium concentration that was close to normal (ranging from 127 to 131",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    The increase in serum sodium relative to placebo in these studies was small (mean, 1 to 5",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    and there was no evidence that long-term outcomes were improved [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/24\">",
"     24",
"    </a>",
"    ]. Although the incidence of correction of the serum sodium by more than 12",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 24 hours with these drugs was low (2 to 4 percent), it is likely that the incidence of overly rapid correction using the definition presented below (more than 8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 24 hours) was considerably higher (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Rate of correction'",
"    </a>",
"    below). In addition, the risk of overly rapid correction would likely be even greater in patients with more severe hyponatremia at baseline. Tolvaptan and conivaptan, but not lixivaptan, are approved for use in the United States. However the United States Food and Drug Administration (FDA) has issued a safety warning about tolvaptan. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Limitations to use of tolvaptan'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following studies illustrate the range of findings in SIADH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effectiveness of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"       conivaptan",
"      </a>",
"      in SIADH was demonstrated in a randomized placebo-controlled trial of 84 hospitalized patients with euvolemic or hypervolemic hyponatremia (serum sodium 115 to &lt;130",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/19\">",
"       19",
"      </a>",
"      ]. Compared with placebo, intravenous conivaptan (20 mg loading dose followed by a continuous infusion of either 40 or 80",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for four days) significantly raised the serum sodium concentration by study end (6.3 and 9.4",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in the 40 and 80",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      arms, respectively, versus 0.8",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      for placebo). The effective free water clearance after 24 hours was approximately two liters with both doses compared to minus 300 mL with placebo.",
"     </li>",
"     <li>",
"      The effects of oral lixivaptan in euvolemic patients with hyponatremia were evaluated in two double-blind placebo-controlled trials (one among outpatients and one among inpatients) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. In the outpatient trial (HARMONY study), 206 patients who had hyponatremia (mean serum sodium 132",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      with or without symptoms were randomly assigned to receive lixivaptan (25 to 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo for 24 weeks, although the majority discontinued therapy early [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/22\">",
"       22",
"      </a>",
"      ]. The serum sodium after seven days of therapy (the primary endpoint) was significantly higher with lixivaptan (135 versus 133",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      and remained significantly higher throughout the remainder of the study. Compared with placebo, lixivaptan had no effect on cognitive function as assessed by two independent instruments. The rate of correction of hyponatremia exceeded 12",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in 24 hours in 2 percent of patients receiving lixivaptan; the proportion of patients correcting more rapidly than 8",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in 24 hours was presumably much higher. Six patients receiving lixivaptan died as compared with one patient in placebo group.",
"      <br/>",
"      <br/>",
"      In the inpatient trial (LIBRA study), 106 hyponatremic patients (mean serum sodium 127",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      with or without symptoms were randomly assigned to lixivaptan (25 to 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo and followed for 30 days [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/23\">",
"       23",
"      </a>",
"      ]. The serum sodium at seven days (the primary outcome) was significantly higher in the lixivaptan group (135 versus 131",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      No effect on cognitive function was observed. Overly rapid correction of hyponatremia occurred in 4 percent of patients receiving lixivaptan and 6 percent of patients receiving placebo. Four patients in the placebo group died as compared with none in the lixivaptan group.",
"     </li>",
"     <li>",
"      The efficacy of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      in ambulatory patients was demonstrated in a combined report of two randomized, double-blind, placebo-controlled multicenter trials (SALT-1 and SALT-2) consisting of 448 patients with hyponatremia (mean serum sodium 129",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      caused by the SIADH (190 patients), heart failure, or cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/17\">",
"       17",
"      </a>",
"      ]. Compared with placebo, tolvaptan significantly increased the serum sodium concentration at day 4 (134 to 135",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      versus 130",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      and day 30 (136 versus 131",
"      <span class=\"nowrap\">",
"       meq/L).",
"       <br/>",
"       <br/>",
"       Among",
"      </span>",
"      all patients in the SALT trials (ie, not limited to those with cirrhosis) who had a serum sodium below 130",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      at baseline, tolvaptan was also associated with a statistically significant improvement in mental status scores. However, the difference was usually not clinically significant and long-term efficacy is uncertain since the duration of follow-up was only 30 days.",
"      <br/>",
"      <br/>",
"      In an open-label extension (called SALTWATER), 111 patients were treated with tolvaptan for a mean follow-up of almost two years [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/25\">",
"       25",
"      </a>",
"      ]. The mean serum sodium was maintained at more than 135",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      compared to 131",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      at baseline. The responses were similar in SIADH and heart failure, and more modest in cirrhosis. The main adverse effects were abnormally frequent urination, thirst, dry mouth, fatigue, polyuria, and polydipsia. Adverse effects that were possibly or probably related to tolvaptan led to discontinuation of therapy in six patients (5.4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there are significant limitations to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Limitations to use of tolvaptan'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Use of conivaptan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"     conivaptan",
"    </a>",
"    requires intravenous administration, it is only useful in the treatment of SIADH in patients who are hospitalized. Its potential role varies with the severity of the hyponatremia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mild to moderate hyponatremia and minimal or no symptoms can be effectively and safely treated with the modalities described above (eg, fluid restriction and salt tablets).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"       Conivaptan",
"      </a>",
"      will more rapidly raise the serum sodium concentration, but it is unclear that is an important advantage in such patients unless it might shorten the duration of hospitalization.",
"     </li>",
"     <li>",
"      Among patients with more severe hyponatremia or mild to moderate symptoms,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"       conivaptan",
"      </a>",
"      can be given alone or in combination with hypertonic saline.",
"     </li>",
"     <li>",
"      Among patients with severe symptomatic hyponatremia,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"       conivaptan",
"      </a>",
"      can be given in combination with hypertonic saline. Since the effect of conivaptan on free water clearance begins as early as one to two hours, it may permit a more rapid initial elevation in serum sodium. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Intravenous saline'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As described below, attention must be paid to avoiding overly rapid correction of the hyponatremia. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Rate of correction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Limitations to use of tolvaptan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    effectively raises the serum sodium concentration in patients with SIADH, as demonstrated in the SALT trials cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/17\">",
"     17",
"    </a>",
"    ], there are important limitations to its use:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concerns about the safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      were raised by a multicenter trial (TEMPO 3:4) that examined its effect on the progression of kidney disease in polycystic kidney disease [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. A greater than 2.5-fold increase in liver enzymes was more common among patients who received tolvaptan compared with placebo. Based upon these data, the US FDA issued a safety warning regarding the use of tolvaptan [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/28\">",
"       28",
"      </a>",
"      ]. The FDA recommends that liver function tests be promptly performed among patients who report symptoms that suggest liver injury, including fatigue, anorexia, right upper quadrant discomfort, dark urine, or jaundice. In addition, we suggest that liver function tests be measured three to four months after initiating therapy and then again at six month intervals. If liver injury is suspected, tolvaptan should be discontinued and not re-initiated unless the cause for liver injury is established to be unrelated. The results of the TEMPO 3:4 trial are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H19#H19\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Vasopressin receptor antagonists'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thirst is increased, which may limit the rise in serum sodium [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There may be overly rapid correction of the hyponatremia, which can lead to irreversible neurologic injury. In the SALT trials, 1.8 percent of patients exceeded the study goal of limiting daily correction to 12",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/17\">",
"       17",
"      </a>",
"      ]. However, more recent recommendations have suggested a maximum rate of correction of hyponatremia of less than 10",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      not &le;12",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Thus, it is almost certain that more than 1.8 percent of treated patients exceeded the currently recommended rate of correction. Because of this risk, hospitalization is required for the initiation or re-initiation of therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of the treatment of hyponatremia\", section on 'Rate of correction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link\">",
"       \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The cost of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      may be prohibitive (as high as $300 per tablet in some areas).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the important limitations to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    , it should only be considered in the rare patients who have a persistent serum sodium below 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or persistent neurologic symptoms that are thought to be due to hyponatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Demeclocycline or lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=see_link\">",
"     Demeclocycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    act on the collecting tubule cell to diminish its responsiveness to ADH, thereby increasing water excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/1,29-31\">",
"     1,29-31",
"    </a>",
"    ]. In patients with bipolar disorder who are treated with chronic lithium therapy, nephrogenic diabetes insipidus develops in up to 20 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal toxicity of lithium\", section on 'Nephrogenic diabetes insipidus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=see_link\">",
"     Demeclocycline",
"    </a>",
"    (300 to 600 mg twice a day) is more predictably effective [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/29\">",
"     29",
"    </a>",
"    ] and more often used than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    for the treatment of hyponatremia in SIADH. However, both drugs can be nephrotoxic; demeclocycline can cause nausea, vomiting, and photosensitivity and costs $10 to $20 per tablet, and lithium has a variety of neuropsychiatric side effects.",
"   </p>",
"   <p>",
"    The goal serum sodium of 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or higher (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Asymptomatic hyponatremia'",
"    </a>",
"    below) can be attained in almost all patients with SIADH with fluid restriction, oral salt tablets alone or with a loop diuretic, and, if necessary and where available, urea. The author and reviewers of this topic rarely use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=see_link\">",
"     demeclocycline",
"    </a>",
"    in such patients and do not use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    . The impairment in concentrating ability with demeclocycline takes several days to one week to become apparent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RATE OF CORRECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among hospitalized patients, the severity of neurologic symptoms attributable to hyponatremia determines the initial rate of correction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with severe neurologic symptoms, which primarily occurs with acute and marked reductions in serum sodium (usually to below 120",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      require rapid initial correction, often with hypertonic saline. However, overly rapid correction should be avoided since it can lead to the late onset of neurologic complications from osmotic demyelination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link\">",
"       \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most patients with SIADH and chronic moderate hyponatremia (serum sodium 120 to 129",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      appear asymptomatic, and slow correction of the hyponatremia is recommended. Some of these \"asymptomatic\" patients have subtle neurologic manifestations that may be improved by raising the serum sodium. These include reduced scores on tests of mental, social, and physical functioning and, in elderly patients, unsteadiness and falls [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/17,32\">",
"       17,32",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Asymptomatic hyponatremia'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal rate of correction is discussed in detail elsewhere. Summarized briefly, the maximum rate of correction of chronic hyponatremia should be less than 9",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in any 24-hour period [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/15,33,34\">",
"     15,33,34",
"    </a>",
"    ]. An initial rate of correction of 4 to 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the first two to four hours may be beneficial in patients with severe symptoms (eg, seizures). This requires careful monitoring of the serum sodium concentration (initially every two to three hours) until the patient is stable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the treatment of hyponatremia\", section on 'Rate of correction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the SIADH resolves while the patient is hyponatremic, ADH secretion will be suppressed by the hypoosmolality, and a water diuresis will ensue. Excretion of a maximally dilute urine will rapidly increase the serum sodium concentration. In selected patients with severe hyponatremia who are correcting too rapidly, prevention of further short-term elevation in serum sodium or even relowering of the serum sodium may be warranted. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link&amp;anchor=H12#H12\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\", section on 'Relowering the serum sodium to treat overly rapid correction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CHOICE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of therapy in patients with hyponatremia due to SIADH varies with the severity of hyponatremia and the presence or absence of symptoms. In addition, patients with a reset osmostat do not require correction of the hyponatremia since they are asymptomatic and have a stable serum sodium. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Reset osmostat'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Symptomatic hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with symptomatic hyponatremia, the approach varies with the severity of the neurologic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Severe symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe symptoms from hyponatremia (eg, seizures, inability to communicate,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coma) are most likely to occur in patients in whom the serum sodium has fallen below 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in less than 48 hours, leading to potentially fatal cerebral edema. Most such cases have been due to the administration of hypotonic intravenous fluids to premenopausal women with postoperative SIADH (",
"    <a class=\"graphic graphic_figure graphicRef76471 \" href=\"UTD.htm?22/23/22909\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H7#H7\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Susceptibility of premenopausal women'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with severe hyponatremic symptoms and in symptomatic patients with underlying intracranial disease who cannot tolerate even minor degrees of brain swelling due to hyponatremia, the serum sodium must initially be raised quickly to prevent possibly irreversible neurologic injury. Based upon broad clinical experience, the administration of hypertonic saline is the only rapid way to raise the serum sodium and improve neurologic manifestations in patients with severe symptomatic hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One regimen that can achieve this goal was initially described in hyponatremic athletes participating in endurance events, such as marathon races [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/11,37,38\">",
"     11,37,38",
"    </a>",
"    ]. It consists of 100 mL of 3 percent saline given as an intravenous bolus, which will raise the serum sodium by approximately 1.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in men and 2.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in women. The rise in serum sodium will pull water out of the brain, decreasing the degree of cerebral edema.",
"   </p>",
"   <p>",
"    If neurologic symptoms persist or worsen, a 100 mL bolus of 3 percent saline can be repeated one or two more times at ten minute intervals. The rationale for this approach is that, in patients with symptomatic hyponatremia, rapid increases in serum sodium of 4 to 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    can reverse severe symptoms such as seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/4,11,39\">",
"     4,11,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the treatment of hyponatremia\", section on 'Severe symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the reasons noted above, there is",
"    <strong>",
"     no role",
"    </strong>",
"    for the use of isotonic saline in symptomatic patients with hyponatremia due to SIADH. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Intravenous saline'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1706?source=see_link&amp;anchor=H19#H19\">",
"     \"Exercise-associated hyponatremia\", section on 'Use of hypertonic saline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the symptoms resolve, careful monitoring with measurement of the serum sodium concentration every two to three hours is required for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A potential complication of hypertonic saline therapy is overly rapid correction of the hyponatremia, particularly in patients with self-limited or reversible SIADH. The usual goals are an elevation in serum sodium of less than 10",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in the first 24 hours and less than 18",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in the first 48 hours. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Rate of correction'",
"      </a>",
"      above.) If symptoms have resolved but the rise in serum sodium is substantially less than the 24 hour goal, further therapy in addition to fluid restriction may consist of a slow infusion of hypertonic saline (eg, 10 to 30 mL per hour) with careful monitoring of the serum sodium.",
"      <br/>",
"      <br/>",
"      In patients with severe hyponatremia who are correcting too rapidly, prevention of further short-term elevation in the serum sodium or even relowering of the serum sodium may be warranted. How this can be achieved is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link&amp;anchor=H12#H12\">",
"       \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\", section on 'Relowering the serum sodium to treat overly rapid correction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with a highly concentrated urine (eg, above 500",
"      <span class=\"nowrap\">",
"       mosmol/kg),",
"      </span>",
"      the serum sodium will come back down toward baseline as the administered sodium is excreted in the urine unless further therapy is given. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Intravenous saline'",
"      </a>",
"      above.) In such patients, the urine osmolality can be reduced by administration of a loop diuretic (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      20 mg orally twice a day).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Mild to moderate symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less severe neurologic symptoms (eg, dizziness, gait disturbances, forgetfulness, confusion, and lethargy) can be seen in patients with a serum sodium concentration below 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    that develops over more than 48 hours, in patients with a lesser degree of hyponatremia that develops over less than 48 hours, and in patients with chronic moderate hyponatremia (serum sodium 120 to 129",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    Some of these patients may benefit from hypertonic saline, but do not require the aggressive approach suggested in the preceding section for those with severe neurologic symptoms.",
"   </p>",
"   <p>",
"    Initial hypertonic saline therapy to raise the serum sodium at rates up to 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    per hour may be justified in the first three to four hours in patients with distressing symptoms (eg, confusion and lethargy). In the calculations described above, 500 mL of hypertonic saline initially raised the serum sodium by 6.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in a 60 kg woman and 4.6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in a 70 kg man. Thus, raising the serum sodium by 4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in four hours would require approximately 310 mL (75 mL per hour) of hypertonic saline in the woman and 435 mL (110 mL per hour) in the man. These calculations are only estimates and the serum sodium should be measured at two to three hours. The total elevation in serum sodium in the first 24 hours should be less than 10",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Intravenous saline'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with less severe symptoms can be treated with less aggressive therapy, such as fluid restriction and oral salt tablets.",
"   </p>",
"   <p>",
"    Once the symptoms have resolved, further therapy is similar to that in patients with SIADH who have asymptomatic hyponatremia, with the caveat of avoidance of overly rapid correction. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Asymptomatic hyponatremia'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Rate of correction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless the SIADH is reversible (eg, postoperative or due to a drug that can be discontinued), effective therapy of symptomatic hyponatremia must be followed by maintenance therapy to prevent a subsequent reduction in serum sodium and possible symptom recurrence. The goal serum sodium is discussed below. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Asymptomatic hyponatremia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One or more of the above therapeutic modalities may be required. The usual sequence of maintenance therapy is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid restriction &ndash; The suggested goal fluid intake in hyponatremic patients with SIADH is less than 800",
"      <span class=\"nowrap\">",
"       mL/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/4\">",
"       4",
"      </a>",
"      ]. An important exception is patients with a recent subarachnoid hemorrhage in whom fluid restriction can be deleterious. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Fluid restriction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Subarachnoid hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral salt &ndash; In patients with SIADH, administering oral salt will increase the urine output; the usual initial dose is 3 g or one-half teaspoon three times daily, resulting in a total dose of 9 g per day. Since sodium handling is normal and the urine osmolality is relatively fixed in SIADH, increasing oral salt intake will, in a dose-dependent fashion, increase the urine volume. In calculations described above, the intake of 9 g of salt (154 meq each of sodium and chloride [308 mosmol]) would be expected to increase the urine output by approximately 500 mL if the urine osmolality is 616",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      and by approximately 1000 mL if the urine osmolality is 308",
"      <span class=\"nowrap\">",
"       mosmol/kg.",
"      </span>",
"      In a 60 kg woman, this extra loss of water will tend to raise the serum sodium by 2.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      if the urine osmolality is 616",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      and by 4.1",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      if the urine osmolality is 308",
"      <span class=\"nowrap\">",
"       mosmol/kg.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Oral salt tablets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reduce the urine osmolality &ndash; In patients with more severe SIADH (urine osmolality more than twice the plasma osmolality), the efficacy of both fluid restriction and increased salt intake will be reduced. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Intravenous saline'",
"      </a>",
"      above.) If further therapy is necessary, the next step is to increase urinary water excretion by impairing the mechanism of urinary concentration. This can be achieved by loop diuretic therapy (eg, furosemide 20 mg orally twice a day). Loop diuretic therapy can produce hypokalemia and hypovolemia since the diuretic response is higher in patients with SIADH who usually have normal or near normal renal function and are not sodium-avid. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Salt plus a loop diuretic'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the reasons described above, we do not use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=see_link\">",
"     demeclocycline",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    for maintenance therapy in patients with asymptomatic hyponatremia. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Limitations to use of tolvaptan'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Demeclocycline or lithium'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Asymptomatic hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic moderate hyponatremia (serum sodium 120 to 129",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    are typically asymptomatic on routine history. Before considering therapy, any reversible cause of SIADH should be addressed. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Treat the underlying disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with asymptomatic hyponatremia have often been treated only with fluid restriction if the cause of the SIADH cannot be corrected. However, some of these seemingly asymptomatic patients have subtle neurologic manifestations that can interfere with the quality of life and that may be improved by raising the serum sodium as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SALT trials described above,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      improved scores on tests of mental, social, and physical functioning among patients with a baseline serum sodium below 130",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/17\">",
"       17",
"      </a>",
"      ]. However, the difference in mental status testing in the SALT trials was usually not clinically significant and long-term efficacy is uncertain since the duration of follow-up was only 30 days. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Vasopressin receptor antagonists'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H6#H6\">",
"       \"Manifestations of hyponatremia and hypernatremia\", section on 'Subtle manifestations in mild to moderate chronic hyponatremia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a study of elderly patients who presented to the Emergency Department, those with asymptomatic chronic hyponatremia (serum sodium between 120 and 129",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      compared to normonatremic controls had an increased incidence of falls that may have resulted from marked impairments in gait and attention [",
"      <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/32\">",
"       32",
"      </a>",
"      ]. Improvement was seen with repeat testing after treatment of the hyponatremia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations suggest that some and perhaps many apparently asymptomatic patients with moderate chronic hyponatremia (serum sodium 120 to 129",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    have subtle reversible neurologic manifestations and that aiming for a goal serum sodium of 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or higher might be beneficial. Data demonstrating efficacy for routine attainment of this goal are not available.",
"   </p>",
"   <p>",
"    If it is elected to aim for a serum sodium of 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or higher in patients with SIADH who do not have overt evidence of neurologic dysfunction, we begin with fluid restriction and, if necessary, add oral salt tablets, and then, if necessary, a loop diuretic in patients with a urine osmolality more than twice that of the plasma. (See appropriate sections above).",
"   </p>",
"   <p>",
"    Given the limitations cited above, we do not recommend the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=see_link\">",
"     demeclocycline",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    to achieve this goal in asymptomatic patients. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Limitations to use of tolvaptan'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Demeclocycline or lithium'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RESET OSMOSTAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal individuals, plasma antidiuretic hormone (ADH, arginine vasopressin) levels are very low when the plasma osmolality is below 280 mosmol",
"    <span class=\"nowrap\">",
"     /kg,",
"    </span>",
"    thereby permitting excretion of ingested water, and increase progressively as the plasma osmolality rises above 280",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef65195 \" href=\"UTD.htm?14/61/15325\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hyponatremia due to downward resetting of osmostat is one form of the SIADH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/1,40-42\">",
"     1,40-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Patterns of ADH secretion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Downward resetting of the osmostat can also occur in hypovolemic states (in which the baroreceptor stimulus to ADH release is superimposed upon osmoreceptor function), quadriplegia (in which effective volume depletion may result from venous pooling in the legs), psychosis, tuberculosis, and chronic malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/1,40\">",
"     1,40",
"    </a>",
"    ]. The serum sodium concentration also falls by about 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in normal pregnancy. No therapy is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link\">",
"     \"Renal and urinary tract physiology in normal pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of a reset osmostat should be suspected in any patient with apparent SIADH who has mild hyponatremia (usually between 125 and 135",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    that is stable over many days despite variations in sodium and water intake. The diagnosis can be confirmed clinically by observing the response to a water load (10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    given orally or intravenously). Normal subjects and those with a reset osmostat should excrete more than 80 percent of the water load within four hours, while excretion will be impaired in the SIADH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identification of a reset osmostat is important because the above therapeutic recommendations for the SIADH may not apply [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/1,40,43\">",
"     1,40,43",
"    </a>",
"    ]. These patients have mild to moderate asymptomatic hyponatremia in which there is downward resetting of the threshold for both ADH release and thirst. Since osmoreceptor function is normal around the new baseline, attempting to raise the serum sodium concentration will increase ADH levels and make the patient thirsty, a response that is similar to that seen with fluid restriction in normal subjects.",
"   </p>",
"   <p>",
"    Thus, attempting to raise the serum sodium concentration may be unnecessary (given the apparent lack of symptoms and lack of risk of more severe hyponatremia) and likely to be ineffective (due to increased thirst). Treatment should be primarily directed at the underlying disease, such as tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/57/17306/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     INFORMATION FOR PATIENTS",
"    </strong>",
"    &mdash; UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/20/9537?source=see_link\">",
"       \"Patient information: Hyponatremia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/29/13777?source=see_link\">",
"       \"Patient information: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with SIADH, hyponatremia is caused by the combination of ADH-induced water retention and secondary solute loss. With chronic SIADH, overall solute loss is more prominent than water retention. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of hyponatremia in SIADH involves treatment of the underlying disease and therapies to raise and maintain the serum sodium. Causes of SIADH that can be effectively treated include adrenal insufficiency and hypothyroidism, infections such as meningitis, pneumonia, or tuberculosis, and drug-induced disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treat the underlying disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Therapies to raise the serum sodium",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid restriction is the mainstay of the treatment of most patients with SIADH, with a suggested goal intake of less than 800",
"      <span class=\"nowrap\">",
"       mL/day;",
"      </span>",
"      patients with subarachnoid hemorrhage are an exception since fluid restriction may promote cerebral vasospasm. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Fluid restriction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to fluid restriction, the therapy of SIADH-associated hyponatremia often requires the administration of sodium chloride, either as oral salt tablets or intravenous saline. When using intravenous saline, the electrolyte concentration of the administered fluid must be greater than the electrolyte concentration of the urine. This usually requires the use of hypertonic saline. Isotonic saline is infrequently effective and often leads to further lowering of the serum sodium. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Intravenous saline'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Oral salt tablets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with a urine osmolality more than twice the plasma osmolality (which typically means a urine osmolality above 500",
"      <span class=\"nowrap\">",
"       mosmol/kg),",
"      </span>",
"      a loop diuretic may be used to reduce urinary concentration, thereby increasing water excretion. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Salt plus a loop diuretic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vasopressin receptor antagonists produce a selective water diuresis without affecting sodium and potassium excretion. Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"       conivaptan",
"      </a>",
"      (which is used in hospitalized patients) and oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      are available and approved for use in patients with hyponatremia due to SIADH. The utility of tolvaptan therapy is limited by concerns about hepatotoxicity, excessive thirst, prohibitive cost (at least in the United States), and the potential for overly rapid correction of the hyponatremia which has led to the necessity for hospitalization for the initiation of therapy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Vasopressin receptor antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The maximum rate of correction of chronic hyponatremia should be less than 10",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      at 24 hours and less than 18",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      at 48 hours. The serum sodium concentration should be checked at two to three hours initially and then every three to four hours until the patient is stable. In selected patients with severe hyponatremia who are correcting too rapidly, prevention of further short-term elevation in serum sodium or even relowering of the serum sodium may be warranted. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Rate of correction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link&amp;anchor=H12#H12\">",
"       \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\", section on 'Relowering the serum sodium to treat overly rapid correction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Choosing the appropriate therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of therapy in patients with hyponatremia due to SIADH varies with the severity of hyponatremia and the presence or absence of symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with severe symptomatic hyponatremia who present with seizures or other severe neurologic abnormalities or with symptomatic hyponatremia in patients with intracerebral diseases, we recommend urgent intervention with hypertonic saline rather than other therapies (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). An effective initial regimen is 100 mL of 3 percent saline given as an intravenous bolus, which should raise the serum sodium concentration by approximately 1.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in men and 2.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in women, thereby reducing the degree of cerebral edema. If neurologic symptoms persist or worsen, a 100 mL bolus of 3 percent saline can be repeated one or two more times at ten minute intervals. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Severe symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients have less severe neurologic manifestations and a serum sodium concentration below 120",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      that develops over more than 48 hours, a lesser degree of hyponatremia that develops over less than 48 hours, or chronic moderate hyponatremia (serum sodium 120 to 129",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      Initial therapy in these patients depends in part upon the severity of symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with confusion and lethargy, we recommend the initial administration of hypertonic saline therapy to raise the serum sodium (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The goal is to raise the serum sodium 1",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per hour for three to four hours. The serum sodium should be measured at two to three hours and the subsequent infusion rate should be adjusted to achieve a rate of correction of less than 10",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      at 24 hours and less than 18",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      at 48 hours.",
"     </li>",
"     <li>",
"      For patients who have only mild symptoms (eg, forgetfulness, gait disturbance), we suggest initial therapy with fluid restriction and oral salt tablets rather than hypertonic saline. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Mild to moderate symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance therapy in patients who initially had symptomatic hyponatremia may prevent a subsequent reduction in serum sodium and possible symptom recurrence. We suggest fluid restriction to less than 800",
"      <span class=\"nowrap\">",
"       mL/day.",
"      </span>",
"      If the serum sodium is persistently less than 130",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      we add oral salt tablets and, if necessary in patients with a urine osmolality more than twice that of the plasma, a loop diuretic (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      20 mg orally twice a day). We would not use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=see_link\">",
"       demeclocycline",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      in asymptomatic patients given the limitations cited above. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Maintenance therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Demeclocycline or lithium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among asymptomatic patients with SIADH, we initiate therapy with fluid restriction. Oral salt tablets may be added, and then, if necessary in patients with a urine osmolality more than twice that of the plasma, a loop diuretic. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Asymptomatic hyponatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyponatremia with a reset osmostat pattern is a variant of the SIADH and should be suspected in any patient with mild to moderate hyponatremia (usually between 125 and 135",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      that is stable over time despite variations in sodium and water intake. The therapeutic recommendations for SIADH do not apply to patients with reset osmostat. Treatment should be primarily directed at the underlying disease. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Reset osmostat'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Goal serum sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest a goal serum sodium of 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or higher in patients with SIADH because of the possible presence of subtle neurologic manifestations and falls when the serum sodium is between 120 and 129",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Asymptomatic hyponatremia'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.729.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/2\">",
"      Cooke CR, Turin MD, Walker WG. The syndrome of inappropriate antidiuretic hormone secretion (SIADH): pathophysiologic mechanisms in solute and volume regulation. Medicine (Baltimore) 1979; 58:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/3\">",
"      Verbalis JG. Pathogenesis of hyponatremia in an experimental model of the syndrome of inappropriate antidiuresis. Am J Physiol 1994; 267:R1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/4\">",
"      Adrogu&eacute; HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/5\">",
"      Rose BD. New approach to disturbances in the plasma sodium concentration. Am J Med 1986; 81:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/6\">",
"      Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356:2064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/7\">",
"      Wijdicks EF, Vermeulen M, Murray GD, et al. The effects of treating hypertension following aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg 1990; 92:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/8\">",
"      Sterns RH, Silver SM. Cerebral salt wasting versus SIADH: what difference? J Am Soc Nephrol 2008; 19:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/9\">",
"      Woo CH, Rao VA, Sheridan W, Flint AC. Performance characteristics of a sliding-scale hypertonic saline infusion protocol for the treatment of acute neurologic hyponatremia. Neurocrit Care 2009; 11:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/10\">",
"      Steele A, Gowrishankar M, Abrahamson S, et al. Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination. Ann Intern Med 1997; 126:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/11\">",
"      Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol 2009; 29:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/12\">",
"      Decaux G, Waterlot Y, Genette F, et al. Inappropriate secretion of antidiuretic hormone treated with frusemide. Br Med J (Clin Res Ed) 1982; 285:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/13\">",
"      Decaux G, Brimioulle S, Genette F, Mockel J. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Med 1980; 69:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/14\">",
"      Decaux G, Genette F. Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone. Br Med J (Clin Res Ed) 1981; 283:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/15\">",
"      Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007; 120:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/16\">",
"      Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006; 69:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/17\">",
"      Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/18\">",
"      Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006; 1:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/19\">",
"      Zeltser D, Rosansky S, van Rensburg H, et al. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007; 27:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/20\">",
"      Saito T, Ishikawa S, Abe K, et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 1997; 82:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/21\">",
"      Murphy T, Dhar R, Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care 2009; 11:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/22\">",
"      Abraham WT, Decaux G, Josiassen RC, et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney Int 2012; 82:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/23\">",
"      Abraham WT, Hensen J, Gross PA, et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney Int 2012; 82:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/24\">",
"      Borne RT, Krantz MJ. Lixivaptan for hyponatremia--the numbers game. JAMA 2012; 308:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/25\">",
"      Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/26\">",
"      Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 2011; 6:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/27\">",
"      Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367:2407.",
"     </a>",
"    </li>",
"    <li>",
"     Samsca (tolvaptan): Drug Warning - Potential Risk of Liver Injury file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm336669.htm?source=govdelivery (Accessed on January 28, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/29\">",
"      Forrest JN Jr, Cox M, Hong C, et al. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1978; 298:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/30\">",
"      Cox M, Guzzo J, Morrison G, Singer I. Demeclocycline and therapy of hyponatremia. Ann Intern Med 1977; 86:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/31\">",
"      Gr&uuml;nfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/32\">",
"      Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006; 119:71.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/33\">",
"      Sterns RH, Hix JK, Silver S. Treatment of hyponatremia. Curr Opin Nephrol Hypertens 2010; 19:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/34\">",
"      Adrogu&eacute; HJ, Madias NE. The challenge of hyponatremia. J Am Soc Nephrol 2012; 23:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/35\">",
"      Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med 1992; 117:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/36\">",
"      Arieff AI, Ayus JC. Endometrial ablation complicated by fatal hyponatremic encephalopathy. JAMA 1993; 270:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/37\">",
"      Ayus JC, Arieff A, Moritz ML. Hyponatremia in marathon runners. N Engl J Med 2005; 353:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/38\">",
"      Hew-Butler T, Ayus JC, Kipps C, et al. Statement of the Second International Exercise-Associated Hyponatremia Consensus Development Conference, New Zealand, 2007. Clin J Sport Med 2008; 18:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/39\">",
"      Siegel AJ, Verbalis JG, Clement S, et al. Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion. Am J Med 2007; 120:461.e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/40\">",
"      Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med 2006; 119:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/41\">",
"      Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int 1976; 10:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/42\">",
"      DeFronzo RA, Goldberg M, Agus ZS. Normal diluting capacity in hyponatremic patients. Reset osmostat or a variant of the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med 1976; 84:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/43\">",
"      Kahn T. Reset osmostat and salt and water retention in the course of severe hyponatremia. Medicine (Baltimore) 2003; 82:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/57/17306/abstract/44\">",
"      Hill AR, Uribarri J, Mann J, Berl T. Altered water metabolism in tuberculosis: role of vasopressin. Am J Med 1990; 88:357.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2357 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17306=[""].join("\n");
var outline_f16_57_17306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THERAPIES TO RAISE THE SERUM SODIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treat the underlying disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fluid restriction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Intravenous saline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H155108392\">",
"      High solute intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Oral salt tablets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Salt plus a loop diuretic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Urea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vasopressin receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Use of conivaptan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Limitations to use of tolvaptan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Demeclocycline or lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RATE OF CORRECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CHOICE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Symptomatic hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Severe symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Mild to moderate symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Asymptomatic hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RESET OSMOSTAT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Therapies to raise the serum sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Choosing the appropriate therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Goal serum sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2357\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2357|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/23/22909\" title=\"figure 1\">",
"      Hyponatremia demyelination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/61/15325\" title=\"figure 2\">",
"      Osmoregulation of ADH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8567?source=related_link\">",
"      Cerebral salt-wasting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1706?source=related_link\">",
"      Exercise-associated hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=related_link\">",
"      Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/20/9537?source=related_link\">",
"      Patient information: Hyponatremia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/29/13777?source=related_link\">",
"      Patient information: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=related_link\">",
"      Renal toxicity of lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_57_17307="Effects of testosterone deficiency";
var content_f16_57_17307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Effects of testosterone deficiency according to age at onset",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effects of testosterone deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        First trimester in utero",
"       </td>",
"       <td>",
"        Incomplete virilization of external genitalia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incomplete development of Wolffian ducts to form male internal genitalia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Third trimester in utero",
"       </td>",
"       <td>",
"        Micropenis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Prepuberty",
"       </td>",
"       <td>",
"        Incomplete pubertal maturation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eunuchoidal body habitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor muscle development and reduced peak bone mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Postpuberty",
"       </td>",
"       <td>",
"        Decrease in energy, mood, and libido",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decrease in sexual hair, hematocrit, muscle mass and strength, and bone mineral density",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17307=[""].join("\n");
var outline_f16_57_17307=null;
var title_f16_57_17308="Causes of primary adrenal insufficiency";
var content_f16_57_17308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of adrenal insufficiency (Addison's disease)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Autoimmune adrenalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolated adrenal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyglandular autoimmune syndrome type I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyglandular autoimmune syndrome type II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infectious adrenalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Disseminated fungal infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Histoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Paracoccidioidomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV infection and AIDS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        African trypanosomiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Metastatic cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primarily lung, breast, stomach and colon cancer or lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Adrenal hemorrhage or infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ketoconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barbiturates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Megestrol acetate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other: aminoglutethimide, etomidate, metyrapone, suramin, mitotane",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenoleukodystrophy and adrenomyeloneuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital adrenal hypoplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial glucocorticoid deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial glucocorticoid resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Defective cholesterol metabolism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17308=[""].join("\n");
var outline_f16_57_17308=null;
var title_f16_57_17309="Past month illicit drug use ages 12 and older 2008";
var content_f16_57_17309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F73465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F73465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Past month illicit drug use among persons ages 12 and older - 2008",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 377px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Includes marijuana/hashish, cocaine (including crack), heroin, hallucinogens, inhalants, or prescription-type psychotherapeutics used nonmedically.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Office of Applied Studies. National Survey on Drug Use and Health, 2008. Substance Abuse and Mental Health Services Administration, Rockville, MD, 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17309=[""].join("\n");
var outline_f16_57_17309=null;
var title_f16_57_17310="Epidemiology of trachoma";
var content_f16_57_17310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epidemiology of trachoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 312px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Active infection with Chlamydia trachomatis is mostly seen in young children with a peak incidence before age 10, while subsequent scarring and blindness is seen in adults.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17310=[""].join("\n");
var outline_f16_57_17310=null;
var title_f16_57_17311="Intravenous pyelogram showing massive bilateral hydronephrosis";
var content_f16_57_17311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intravenous pyelogram showing massive bilateral hydronephrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intravenous pyelogram showing massive bilateral hydronephrosis and ureteral dilatation (arrow) due to urinary tract obstruction which, as shown in the next film, is due to ureterovesical obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Rose BD, Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York, 1987.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_57_17311=[""].join("\n");
var outline_f16_57_17311=null;
